<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
	<head>
		<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
		<meta http-equiv="Content-Style-Type" content="text/css" />
		<meta name="generator" content="MediaWiki 1.15alpha" />
		<meta name="keywords" content="Duloxetine,Medicine,Medicine articles needing expert attention,Articles to be expanded since May 2008,Articles with unsourced statements since May 2007,Articles with unsourced statements since May 2008,Articles with unsourced statements since September 2007,Antidepressants,2006,5-HT receptor,ATC code N06" />
		<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Duloxetine&amp;action=edit" />
		<link rel="edit" title="Edit this page" href="/w/index.php?title=Duloxetine&amp;action=edit" />
		<link rel="apple-touch-icon" href="http://en.wikipedia.org/apple-touch-icon.png" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)" />
		<link rel="copyright" href="http://www.gnu.org/copyleft/fdl.html" />
		<link rel="alternate" type="application/rss+xml" title="Wikipedia RSS Feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=rss" />
		<link rel="alternate" type="application/atom+xml" title="Wikipedia Atom Feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=atom" />
		<title>Duloxetine - Wikipedia, the free encyclopedia</title>
		<link rel="stylesheet" href="/skins-1.5/common/shared.css?207xx" type="text/css" media="screen" />
		<link rel="stylesheet" href="/skins-1.5/common/commonPrint.css?207xx" type="text/css" media="print" />
		<link rel="stylesheet" href="/skins-1.5/monobook/main.css?207xx" type="text/css" media="screen" />
		<link rel="stylesheet" href="/skins-1.5/chick/main.css?207xx" type="text/css" media="handheld" />
		<!--[if lt IE 5.5000]><link rel="stylesheet" href="/skins-1.5/monobook/IE50Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<!--[if IE 5.5000]><link rel="stylesheet" href="/skins-1.5/monobook/IE55Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<!--[if IE 6]><link rel="stylesheet" href="/skins-1.5/monobook/IE60Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<!--[if IE 7]><link rel="stylesheet" href="/skins-1.5/monobook/IE70Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Common.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" />
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Print.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" media="print" />
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Handheld.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" media="handheld" />
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Monobook.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" />
		<link rel="stylesheet" href="/w/index.php?title=-&amp;action=raw&amp;maxage=2678400&amp;gen=css" type="text/css" />
		<!--[if lt IE 7]><script type="text/javascript" src="/skins-1.5/common/IEFixes.js?207xx"></script>
		<meta http-equiv="imagetoolbar" content="no" /><![endif]-->

		<script type= "text/javascript">/*<![CDATA[*/
		var skin = "monobook";
		var stylepath = "/skins-1.5";
		var wgArticlePath = "/wiki/$1";
		var wgScriptPath = "/w";
		var wgScript = "/w/index.php";
		var wgVariantArticlePath = false;
		var wgActionPaths = {};
		var wgServer = "http://en.wikipedia.org";
		var wgCanonicalNamespace = "";
		var wgCanonicalSpecialPageName = false;
		var wgNamespaceNumber = 0;
		var wgPageName = "Duloxetine";
		var wgTitle = "Duloxetine";
		var wgAction = "view";
		var wgArticleId = "566616";
		var wgIsArticle = true;
		var wgUserName = null;
		var wgUserGroups = null;
		var wgUserLanguage = "en";
		var wgContentLanguage = "en";
		var wgBreakFrames = false;
		var wgCurRevisionId = 281351451;
		var wgVersion = "1.15alpha";
		var wgEnableAPI = true;
		var wgEnableWriteAPI = true;
		var wgSeparatorTransformTable = ["", ""];
		var wgDigitTransformTable = ["", ""];
		var wgMWSuggestTemplate = "http://en.wikipedia.org/w/api.php?action=opensearch\x26search={searchTerms}\x26namespace={namespaces}\x26suggest";
		var wgDBname = "enwiki";
		var wgSearchNamespaces = [0];
		var wgMWSuggestMessages = ["with suggestions", "no suggestions"];
		var wgRestrictionEdit = [];
		var wgRestrictionMove = [];
		/*]]>*/</script>

		<script type="text/javascript" src="/skins-1.5/common/wikibits.js?207xx"><!-- wikibits js --></script>
		<!-- Head Scripts -->
		<script type="text/javascript" src="/skins-1.5/common/ajax.js?207xx"></script>
		<script type="text/javascript" src="/skins-1.5/common/mwsuggest.js?207xx"></script>
<script type="text/javascript">/*<![CDATA[*/
var wgNotice='';var wgNoticeLocal='';
/*]]>*/</script>		<script type="text/javascript" src="http://upload.wikimedia.org/centralnotice/wikipedia/en/centralnotice.js?207xx"></script>
		<script type="text/javascript" src="/w/index.php?title=-&amp;action=raw&amp;gen=js&amp;useskin=monobook"><!-- site js --></script>
	</head>
<body class="mediawiki ltr ns-0 ns-subject page-Duloxetine skin-monobook">
	<div id="globalWrapper">
		<div id="column-content">
	<div id="content">
		<a name="top" id="top"></a>
		<div id="siteNotice"><script type='text/javascript'>if (wgNotice != '') document.writeln(wgNotice);</script></div>		<h1 id="firstHeading" class="firstHeading">Duloxetine</h1>
		<div id="bodyContent">
			<h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
			<div id="contentSub"></div>
									<div id="jump-to-nav">Jump to: <a href="#column-one">navigation</a>, <a href="#searchInput">search</a></div>			<!-- start content -->
			<table class="metadata plainlinks ambox ambox-content" style="">
<tr>
<td class="mbox-image">
<div style="width: 52px;"><a href="/wiki/File:Ambox_content.png" class="image" title="Ambox content.png"><img alt="" src="http://upload.wikimedia.org/wikipedia/en/f/f4/Ambox_content.png" width="40" height="40" border="0" /></a></div>
</td>
<td class="mbox-text" style="">This article is <b>in need of attention from an expert on the subject</b>. <a href="/wiki/Wikipedia:WikiProject_Medicine" title="Wikipedia:WikiProject Medicine">WikiProject Medicine</a> or the <a href="/wiki/Portal:Medicine" title="Portal:Medicine">Medicine Portal</a> may be able to help recruit one. <small><i>(March 2009)</i></small></td>
</tr>
</table>
<table class="metadata plainlinks ambox ambox-content" style="">
<tr>
<td class="mbox-image">
<div style="width: 52px;"><a href="/wiki/File:Unbalanced_scales.svg" class="image" title="Unbalanced scales.svg"><img alt="" src="http://upload.wikimedia.org/wikipedia/en/thumb/f/fe/Unbalanced_scales.svg/45px-Unbalanced_scales.svg.png" width="45" height="40" border="0" /></a></div>
</td>
<td class="mbox-text" style="">The <b><a href="/wiki/Wikipedia:Neutral_point_of_view" title="Wikipedia:Neutral point of view">neutrality</a> of this article is <a href="/wiki/Wikipedia:NPOV_dispute" title="Wikipedia:NPOV dispute">disputed</a></b>. Please see the discussion on the <a href="/wiki/Talk:Duloxetine" title="Talk:Duloxetine">talk page</a>. Please do not remove this message until the <a href="/wiki/Wikipedia:NPOVD#What_is_an_NPOV_dispute.3F" title="Wikipedia:NPOVD" class="mw-redirect">dispute is resolved.</a> <small><i>(September 2008)</i></small></td>
</tr>
</table>
<table id="drugInfoBox" style="float: right; clear: right; margin: 0 0 0.5em 1em; background: #ffffff;" class="toccolours" border="0" cellpadding="1" align="right" width="280">
<tr>
<td align="center" colspan="2"><a href="/wiki/File:Duloxetine.png" class="image" title="Duloxetine.png"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/2/27/Duloxetine.png/150px-Duloxetine.png" width="150" height="157" border="0" /></a></td>
</tr>
<tr>
<td align="center" colspan="2">
<div style="font-size:medium; line-height:167%;">Duloxetine</div>
</td>
</tr>
<tr>
<td align="center" colspan="2" bgcolor="#DDDDDD"><b>Systematic (<a href="/wiki/International_Union_of_Pure_and_Applied_Chemistry_nomenclature" title="International Union of Pure and Applied Chemistry nomenclature" class="mw-redirect">IUPAC</a>) name</b></td>
</tr>
<tr>
<td bgcolor="#EEEEEE" style="text-align: center; vertical-align: top;" colspan="2"><span style="font-size:11px">(+)-(<i>S</i>)-<i>N</i>-Methyl-3-(naphthalen-1-yloxy)-<br />
3-(thiophen-2-yl)propan-1-amine</span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Identifiers</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" width="90"><a href="/wiki/CAS_registry_number" title="CAS registry number">CAS number</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?term=116539-59-4&amp;rn=1" class="external text" title="http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?term=116539-59-4&amp;rn=1" rel="nofollow">116539-59-4</a></span>  (free base). <a href="http://toolserver.org/~magnus/cas.php?language=en&amp;cas=136434-34-9&amp;title=" class="external text" title="http://toolserver.org/~magnus/cas.php?language=en&amp;cas=136434-34-9&amp;title=" rel="nofollow">136434-34-9</a> (<a href="/wiki/Hydrochloride" title="Hydrochloride">hydrochloride</a>)</td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/Anatomical_Therapeutic_Chemical_Classification_System" title="Anatomical Therapeutic Chemical Classification System">ATC code</a></td>
<td bgcolor="#EEEEEE"><a href="/wiki/ATC_code_N06" title="ATC code N06">N06</a><span class="reflink plainlinksneverexpand"><a href="http://www.whocc.no/atcddd/indexdatabase/index.php?query=N06AX21" class="external text" title="http://www.whocc.no/atcddd/indexdatabase/index.php?query=N06AX21" rel="nofollow">AX21</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/PubChem" title="PubChem">PubChem</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=60835" class="external text" title="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=60835" rel="nofollow">60835</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/DrugBank" title="DrugBank">DrugBank</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://www.drugbank.ca/cgi-bin/show_drug.cgi?CARD=APRD00060" class="external text" title="http://www.drugbank.ca/cgi-bin/show_drug.cgi?CARD=APRD00060" rel="nofollow">APRD00060</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/ChemSpider" title="ChemSpider">ChemSpider</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://www.chemspider.com/Chemical-Structure.54822" class="external text" title="http://www.chemspider.com/Chemical-Structure.54822" rel="nofollow">54822</a></span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Chemical data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/Chemical_formula" title="Chemical formula">Formula</a></td>
<td bgcolor="#EEEEEE"><a href="/wiki/Carbon" title="Carbon"><span style="color: rgb(000,000,000); font-weight: bold;">C</span></a><sub>18</sub><a href="/wiki/Hydrogen" title="Hydrogen"><span style="color: rgb(77,77,77); font-weight: bold;">H</span></a><sub>19</sub><a href="/wiki/Nitrogen" title="Nitrogen"><span style="color: rgb(0,0,128); font-weight: bold;">N</span></a><a href="/wiki/Oxygen" title="Oxygen"><span style="color: rgb(116,35,35); font-weight: bold;">O</span></a><a href="/wiki/Sulfur" title="Sulfur"><span style="color: rgb(114,97,31); font-weight: bold;">S</span></a><sup>&#160;</sup></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/Molecular_mass" title="Molecular mass">Mol. mass</a></td>
<td bgcolor="#EEEEEE">297.41456 g/mol</td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/Simplified_molecular_input_line_entry_specification" title="Simplified molecular input line entry specification">SMILES</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://www.emolecules.com/cgi-bin/search?t=ex&amp;q=CNCC%5BC%40%40H%5D%28C1%3DCC%3DCS1%29OC2%3DCC%3DCC3%3DCC%3DCC%3DC32" class="external text" title="http://www.emolecules.com/cgi-bin/search?t=ex&amp;q=CNCC%5BC%40%40H%5D%28C1%3DCC%3DCS1%29OC2%3DCC%3DCC3%3DCC%3DCC%3DC32" rel="nofollow">eMolecules</a></span> &amp; <span class="reflink plainlinksneverexpand"><a href="http://pubchem.ncbi.nlm.nih.gov/search/?smarts=CNCC%5BC%40%40H%5D%28C1%3DCC%3DCS1%29OC2%3DCC%3DCC3%3DCC%3DCC%3DC32" class="external text" title="http://pubchem.ncbi.nlm.nih.gov/search/?smarts=CNCC%5BC%40%40H%5D%28C1%3DCC%3DCS1%29OC2%3DCC%3DCC3%3DCC%3DCC%3DC32" rel="nofollow">PubChem</a></span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Pharmacokinetic data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Bioavailability" title="Bioavailability">Bioavailability</a></td>
<td bgcolor="#EEEEEE">~ 50% (32% to 80%)</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Plasma_protein_binding" title="Plasma protein binding">Protein binding</a></td>
<td bgcolor="#EEEEEE">~ 95%</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Drug_metabolism" title="Drug metabolism">Metabolism</a></td>
<td bgcolor="#EEEEEE">Liver, two P450 isozymes, <a href="/wiki/CYP2D6" title="CYP2D6">CYP2D6</a> and <a href="/wiki/CYP1A2" title="CYP1A2">CYP1A2</a>.</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Biological_half-life" title="Biological half-life">Half life</a></td>
<td bgcolor="#EEEEEE">12,1 hours</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Excretion" title="Excretion">Excretion</a></td>
<td bgcolor="#EEEEEE">70% in urine, 20% in feces</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Therapeutic considerations</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/Regulation_of_therapeutic_goods" title="Regulation of therapeutic goods">Licence data</a></td>
<td bgcolor="#EEEEEE">
<p><a href="/wiki/European_Medicines_Agency" title="European Medicines Agency">EU EMEA</a>:<span class="reflink plainlinksneverexpand"><a href="http://www.emea.europa.eu/humandocs/Humans/EPAR/Ariclaim/Ariclaim.htm" class="external text" title="http://www.emea.europa.eu/humandocs/Humans/EPAR/Ariclaim/Ariclaim.htm" rel="nofollow">link</a></span>,&#160;<a href="/wiki/U.S._Food_and_Drug_Administration" title="U.S. Food and Drug Administration">US FDA</a>:<span class="reflink plainlinksneverexpand"><a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&amp;SearchTerm=duloxetine&amp;SearchType=BasicSearch" class="external text" title="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&amp;SearchTerm=duloxetine&amp;SearchType=BasicSearch" rel="nofollow">link</a></span></p>
</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Pregnancy_category" title="Pregnancy category">Pregnancy cat.</a></td>
<td bgcolor="#EEEEEE">
<p>C<small>(<a href="/wiki/United_States" title="United States">US</a>)</small></p>
</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Regulation_of_therapeutic_goods" title="Regulation of therapeutic goods">Legal status</a></td>
<td bgcolor="#EEEEEE"></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Route_of_administration" title="Route of administration">Routes</a></td>
<td bgcolor="#EEEEEE">Oral</td>
</tr>
</table>
<div class="thumb tright">
<div class="thumbinner" style="width:182px;"><a href="/wiki/File:Cymbalta60mg.png" class="image" title="Cymbalta 60mg"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/d/dd/Cymbalta60mg.png/180px-Cymbalta60mg.png" width="180" height="95" border="0" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Cymbalta60mg.png" class="internal" title="Enlarge"><img src="/skins-1.5/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Cymbalta 60mg</div>
</div>
</div>
<p><b>Duloxetine</b> (brand names <b>Cymbalta</b>, <b>Yentreve</b>) is a <a href="/wiki/Serotonin-norepinephrine_reuptake_inhibitor" title="Serotonin-norepinephrine reuptake inhibitor">serotonin-norepinephrine reuptake inhibitor</a> (SNRI) effective for the treatment of <a href="/wiki/Major_depressive_disorder" title="Major depressive disorder">major depressive disorder</a> (MDD), <a href="/wiki/General_anxiety_disorder" title="General anxiety disorder" class="mw-redirect">generalized anxiety disorder</a> (GAD), pain related to <a href="/wiki/Diabetic_neuropathy" title="Diabetic neuropathy">diabetic neuropathy</a>, <a href="/wiki/Fibromyalgia" title="Fibromyalgia">fibromyalgia</a> and <a href="/wiki/Stress_urinary_incontinence" title="Stress urinary incontinence" class="mw-redirect">stress urinary incontinence</a> (SUI). Duloxetine has been approved in many countries for the above indications, with the exception of stress <a href="/wiki/Urinary_incontinence" title="Urinary incontinence">urinary incontinence</a> in the US. It is manufactured and marketed by <a href="/wiki/Eli_Lilly" title="Eli Lilly">Eli Lilly</a>.</p>
<p>Large number of side effects occurring during duloxetine treatment and lack of clear advantage over existing medications prompted critical reviews concluding that duloxetine "should not be used" for stress urinary incontinence<sup id="cite_ref-pmid16400743_0-0" class="reference"><a href="#cite_note-pmid16400743-0" title=""><span>[</span>1<span>]</span></a></sup> and "currently has no place in the treatment of depression or diabetic neuropathy" as well.<sup id="cite_ref-pmid17121211_1-0" class="reference"><a href="#cite_note-pmid17121211-1" title=""><span>[</span>2<span>]</span></a></sup><sup id="cite_ref-pmid17451072_2-0" class="reference"><a href="#cite_note-pmid17451072-2" title=""><span>[</span>3<span>]</span></a></sup></p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#History"><span class="tocnumber">1</span> <span class="toctext">History</span></a></li>
<li class="toclevel-1"><a href="#Indications"><span class="tocnumber">2</span> <span class="toctext">Indications</span></a>
<ul>
<li class="toclevel-2"><a href="#Major_depressive_disorder"><span class="tocnumber">2.1</span> <span class="toctext">Major depressive disorder</span></a></li>
<li class="toclevel-2"><a href="#Stress_urinary_incontinence"><span class="tocnumber">2.2</span> <span class="toctext">Stress urinary incontinence</span></a></li>
<li class="toclevel-2"><a href="#Painful_peripheral_neuropathy"><span class="tocnumber">2.3</span> <span class="toctext">Painful peripheral neuropathy</span></a></li>
<li class="toclevel-2"><a href="#Generalized_anxiety_disorder"><span class="tocnumber">2.4</span> <span class="toctext">Generalized anxiety disorder</span></a></li>
<li class="toclevel-2"><a href="#Fibromyalgia"><span class="tocnumber">2.5</span> <span class="toctext">Fibromyalgia</span></a></li>
<li class="toclevel-2"><a href="#Chronic_fatigue_syndrome"><span class="tocnumber">2.6</span> <span class="toctext">Chronic fatigue syndrome</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Contraindications"><span class="tocnumber">3</span> <span class="toctext">Contraindications</span></a></li>
<li class="toclevel-1"><a href="#Adverse_effects"><span class="tocnumber">4</span> <span class="toctext">Adverse effects</span></a>
<ul>
<li class="toclevel-2"><a href="#Postmarketing_spontaneous_reports"><span class="tocnumber">4.1</span> <span class="toctext">Postmarketing spontaneous reports</span></a></li>
<li class="toclevel-2"><a href="#Discontinuation_syndrome"><span class="tocnumber">4.2</span> <span class="toctext">Discontinuation syndrome</span></a></li>
<li class="toclevel-2"><a href="#Suicidality"><span class="tocnumber">4.3</span> <span class="toctext">Suicidality</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Pharmacology"><span class="tocnumber">5</span> <span class="toctext">Pharmacology</span></a></li>
<li class="toclevel-1"><a href="#See_also"><span class="tocnumber">6</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1"><a href="#References"><span class="tocnumber">7</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1"><a href="#External_links"><span class="tocnumber">8</span> <span class="toctext">External links</span></a></li>
</ul>
</td>
</tr>
</table>
<script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script>
<p><a name="History" id="History"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Duloxetine&amp;action=edit&amp;section=1" title="Edit section: History">edit</a>]</span> <span class="mw-headline">History</span></h2>
<p>Duloxetine was created by Lilly researchers. David Robertson, David Wong, a co-discoverer of <a href="/wiki/Fluoxetine" title="Fluoxetine">fluoxetine</a> , and Joseph Krushinski are listed as inventors on the <a href="/wiki/Patent_application" title="Patent application">patent application</a> filed in 1986 and granted in 1990.<sup id="cite_ref-United_States_Patent:_4956388_3-0" class="reference"><a href="#cite_note-United_States_Patent:_4956388-3" title=""><span>[</span>4<span>]</span></a></sup> The first publication on the discovery of the <a href="/wiki/Racemic" title="Racemic" class="mw-redirect">racemic</a> form of duloxetine known as LY227942, was made in 1988.<sup id="cite_ref-4" class="reference"><a href="#cite_note-4" title=""><span>[</span>5<span>]</span></a></sup> The (+)-enantiomer of LY227942, assigned LY248686, was chosen for further studies, because it inhibited serotonin reuptake in rat synaptosomes two times more potently than (-)-enantiomer. This molecule was subsequently named duloxetine.<sup id="cite_ref-pmid14643350_5-0" class="reference"><a href="#cite_note-pmid14643350-5" title=""><span>[</span>6<span>]</span></a></sup></p>
<p>Initial trials conducted in patients using regimens of 20&#160;mg/day or less did not convincingly demonstrate its efficacy <sup id="cite_ref-6" class="reference"><a href="#cite_note-6" title=""><span>[</span>7<span>]</span></a></sup> and the dose was increased to as high as 120&#160;mg in subsequent <a href="/wiki/Clinical_trial" title="Clinical trial">clinical trials</a>.<sup id="cite_ref-pmid11926722_7-0" class="reference"><a href="#cite_note-pmid11926722-7" title=""><span>[</span>8<span>]</span></a></sup></p>
<p>In 2001 Lilly filed a New Drug Application (NDA) for duloxetine with the US <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration" class="mw-redirect">Food and Drug Administration</a> (FDA). However, in 2003 the FDA "recommended this application as not approvable from the manufacturing and control standpoint" because of "significant cGMP violations at the finished product manufacturing facility" of Eli Lilly in Indianapolis. Additionally, "potential liver toxicity" and QTc interval prolongation appeared as a concern. The FDA experts concluded that "Duloxetine can cause hepatotoxicity in the form of transaminase elevations. It may also be a factor in causing more severe liver injury, but there are no cases in the NDA database that clearly demonstrate this. Use of duloxetine in the presence of ethanol may potentiate the deleterious effect of ethanol on the liver." The FDA also recommended "routine blood pressure monitoring" at the new highest recommended dose of 120&#160;mg, "where 24% patients had one or more [blood pressure] readings of 140/90 vs. 9% of placebo patients."<sup id="cite_ref-reg_history_8-0" class="reference"><a href="#cite_note-reg_history-8" title=""><span>[</span>9<span>]</span></a></sup></p>
<p>After the manufacturing issues were resolved, the <a href="/wiki/Hepatotoxicity" title="Hepatotoxicity">liver toxicity</a> warning included in the prescribing information, and the follow-up studies showed that duloxetine does not cause QTc interval prolongation, duloxetine was approved by the FDA for depression and diabetic neuropathy in 2004.<sup id="cite_ref-9" class="reference"><a href="#cite_note-9" title=""><span>[</span>10<span>]</span></a></sup> In 2007 <a href="/wiki/Health_Canada" title="Health Canada">Health Canada</a> approved duloxetine for the treatment of depression and diabetic peripheral neuropathic pain.<sup id="cite_ref-10" class="reference"><a href="#cite_note-10" title=""><span>[</span>11<span>]</span></a></sup></p>
<p>Duloxetine was approved for use of stress urinary incontinence (SUI) in the EU in 2004. In 2005, Lilly withdrew the duloxetine application for stress urinary incontinence (SUI) in the U.S., stating that discussions with the FDA indicated "the agency is not prepared at this time to grant approval ... based on the data package submitted." A year later Lilly abandoned the pursuit of this indication in the U.S. market.<sup id="cite_ref-Yentreve_11-0" class="reference"><a href="#cite_note-Yentreve-11" title=""><span>[</span>12<span>]</span></a></sup></p>
<p><a name="Indications" id="Indications"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Duloxetine&amp;action=edit&amp;section=2" title="Edit section: Indications">edit</a>]</span> <span class="mw-headline">Indications</span></h2>
<p>The main uses of duloxetine are in <a href="/wiki/Major_depressive_disorder" title="Major depressive disorder">major depressive disorder</a>, <a href="/wiki/General_anxiety_disorder" title="General anxiety disorder" class="mw-redirect">general anxiety disorder</a>, <a href="/wiki/Stress_urinary_incontinence" title="Stress urinary incontinence" class="mw-redirect">stress urinary incontinence</a>, painful <a href="/wiki/Peripheral_neuropathy" title="Peripheral neuropathy">peripheral neuropathy</a> and fibromyalgia. In addition, it is being studied for various other indications.</p>
<p><a name="Major_depressive_disorder" id="Major_depressive_disorder"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Duloxetine&amp;action=edit&amp;section=3" title="Edit section: Major depressive disorder">edit</a>]</span> <span class="mw-headline">Major depressive disorder</span></h3>
<p>Duloxetine has demostrated efficacy for the treatment of <a href="/wiki/Major_depressive_disorder" title="Major depressive disorder">major depressive disorder</a>. In three out of six well-designed properly controlled pre-marketing trials duloxetine performed better than placebo; the three other trials were inconclusive.<sup id="cite_ref-FDA-1_12-0" class="reference"><a href="#cite_note-FDA-1-12" title=""><span>[</span>13<span>]</span></a></sup> Recently, duloxetine was shown to be effective in elderly with recurrent major depressive disorder where it improved cognition, depression, and some pain measures. <sup id="cite_ref-13" class="reference"><a href="#cite_note-13" title=""><span>[</span>14<span>]</span></a></sup> A <a href="/wiki/Meta-analysis" title="Meta-analysis">meta-analysis</a> of these trials indicated that the <a href="/wiki/Effect_size" title="Effect size">effect size</a> of duloxetine as compared with placebo was weak-to-moderate, and similar to other 11 antidepressants studied.<sup id="cite_ref-pmid18199864_14-0" class="reference"><a href="#cite_note-pmid18199864-14" title=""><span>[</span>15<span>]</span></a></sup> The rationale behind the development of duloxetine was that <a href="/wiki/Reuptake_inhibitor" title="Reuptake inhibitor">inhibition of the reuptake</a> of both serotonin and norepinephrine would make it work better than <a href="/wiki/Selective_serotonin_reuptake_inhibitor" title="Selective serotonin reuptake inhibitor">selective serotonin reuptake inhibitors</a> (SSRIs), which inhibit only the reuptake of serotonin. However, in a comparative meta-analysis of clinical trials duloxetine appeared to be insignificantly less effective than SSRIs.<sup id="cite_ref-pmid17588546_15-0" class="reference"><a href="#cite_note-pmid17588546-15" title=""><span>[</span>16<span>]</span></a></sup> A head-to-head comparison of duloxetine with an SSRI <a href="/wiki/Escitalopram" title="Escitalopram">escitalopram</a> (Lexapro) found duloxetine to be both less tolerable and less effective.<sup id="cite_ref-pmid18545055_16-0" class="reference"><a href="#cite_note-pmid18545055-16" title=""><span>[</span>17<span>]</span></a></sup> Another analysis of the comparative efficacy of modern antidepressants found duloxetine to be significantly, by 30-40%, less efficacious than <a href="/wiki/Mirtazapine" title="Mirtazapine">mirtazapine</a> (Remeron), escitalopram, <a href="/wiki/Venlafaxine" title="Venlafaxine">venlafaxine</a> (Effexor) and <a href="/wiki/Sertraline" title="Sertraline">sertraline</a> (Zoloft). Duloxetine was similar to <a href="/wiki/Fluoxetine" title="Fluoxetine">fluoxetine</a> (Prozac), <a href="/wiki/Fluvoxamine" title="Fluvoxamine">fluvoxamine</a> (Luvox) and <a href="/wiki/Paroxetine" title="Paroxetine">paroxetine</a> (Paxil). The tolerability of duloxetine was significantly worse than the tolerability of escitalopram and sertraline.<sup id="cite_ref-pmid19185342_17-0" class="reference"><a href="#cite_note-pmid19185342-17" title=""><span>[</span>18<span>]</span></a></sup></p>
<p>A review in Prescrire International summarizing the existing evidence noted that duloxetine has limited efficacy in depression, and has not yet have been shown to be better than any other antidepressant. Prescrire observed that, taking into account the risk of hepatic disorders and drug interactions, there is no reason to chose duloxetine when so many other options are available.<sup id="cite_ref-pmid17121211_1-1" class="reference"><a href="#cite_note-pmid17121211-1" title=""><span>[</span>2<span>]</span></a></sup> Similar analysis was presented by <a href="/wiki/Drug_and_Therapeutics_Bulletin" title="Drug and Therapeutics Bulletin">Drug and Therapeutics Bulletin</a>, which is a part of the respected <a href="/wiki/BMJ_Group" title="BMJ Group">BMJ Group</a>.<sup id="cite_ref-18" class="reference"><a href="#cite_note-18" title=""><span>[</span>19<span>]</span></a></sup></p>
<p><a name="Stress_urinary_incontinence" id="Stress_urinary_incontinence"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Duloxetine&amp;action=edit&amp;section=4" title="Edit section: Stress urinary incontinence">edit</a>]</span> <span class="mw-headline">Stress urinary incontinence</span></h3>
<p>Duloxetine was first reported to improve outcomes in <a href="/wiki/Stress_urinary_incontinence" title="Stress urinary incontinence" class="mw-redirect">stress urinary incontinence</a> (SUI) in 1998.<sup id="cite_ref-19" class="reference"><a href="#cite_note-19" title=""><span>[</span>20<span>]</span></a></sup> <a href="/wiki/Systematic_review" title="Systematic review">Systematic reviews</a> with meta-analysis, conducted in 2005 by <a href="/wiki/Cochrane_Collaboration" title="Cochrane Collaboration">Cochrane Collaboration</a> <sup id="cite_ref-cochrane_20-0" class="reference"><a href="#cite_note-cochrane-20" title=""><span>[</span>21<span>]</span></a></sup> and in 2008 by <a href="/wiki/University_of_Minnesota" title="University of Minnesota">University of Minnesota</a>,<sup id="cite_ref-UM_21-0" class="reference"><a href="#cite_note-UM-21" title=""><span>[</span>22<span>]</span></a></sup> concluded that duloxetine failed to cure SUI better than placebo. According to the Cochrane review, some studies showed that episodes of incontinence were reduced by about 50%. This was associated with an improvement in <a href="/wiki/Quality_of_life" title="Quality of life">quality of life</a> measurements.<sup id="cite_ref-cochrane_20-1" class="reference"><a href="#cite_note-cochrane-20" title=""><span>[</span>21<span>]</span></a></sup> According to the University of Minnesota review, duloxetine performed worse than <a href="/wiki/Oxybutynin" title="Oxybutynin">oxybutynin</a> (Ditropan) or <a href="/wiki/Tolterodine" title="Tolterodine">tolterodine</a> (Detrol) that cured 18% of the cases, or than <a href="/wiki/Kegel_exercise" title="Kegel exercise">pelvic floor muscle training</a> + bladder training, which cured 13% of the cases. In terms of "improvement", that is incomplete cure, duloxetine showed improvement in 11% of patients while <a href="/wiki/Pelvic_floor" title="Pelvic floor">pelvic floor</a> muscle training + bladder training showed improvement in 36% of the cases.<sup id="cite_ref-UM_21-1" class="reference"><a href="#cite_note-UM-21" title=""><span>[</span>22<span>]</span></a></sup> Significant side effects were common with duloxetine; they were reported as acceptable and about a fifth had to discontinue the medication because of poor tolerance.<sup id="cite_ref-cochrane_20-2" class="reference"><a href="#cite_note-cochrane-20" title=""><span>[</span>21<span>]</span></a></sup></p>
<p>In addition, the full report prepared by Minnesota Evidence-based Practice Center for the US government, on which the University of Minnesota review is based, notes that weight reduction would result in improved SUI in 990 adults per 1,000 treated. <sup id="cite_ref-ahrq_22-0" class="reference"><a href="#cite_note-ahrq-22" title=""><span>[</span>23<span>]</span></a></sup> In the light of the cited data, the report does not mention duloxetine in its policy recommendations. The only recommended interventions are early behavioral changes in weight, physical activity, and pelvic floor muscle training.<sup id="cite_ref-ahrq_22-1" class="reference"><a href="#cite_note-ahrq-22" title=""><span>[</span>23<span>]</span></a></sup></p>
<p>The only clinical trial, which directly compared duloxetine with the gold standard of the SUI treatment pelvic floor muscle training (PFMT) was conducted by <a href="/wiki/Eli_Lilly_and_Company" title="Eli Lilly and Company">Eli Lilly</a> and gave mixed results. The incontinence episode frequency in duloxetine group decreased by 57% vs. 35% in the PFTM group. However, the differences in the pad use and quality of life were not statistically significant. To the contrary, 65% patients doing PFTM reported feeling better vs 54% of the patients on duloxetine. 31% of the patients on duloxetine discontinued the trial due to the side effects during the first 12 weeks.<sup id="cite_ref-2615a_23-0" class="reference"><a href="#cite_note-2615a-23" title=""><span>[</span>24<span>]</span></a></sup> In the continuation of this trial more than 91% of the patients on duloxetine experienced side effects.<sup id="cite_ref-2615b_24-0" class="reference"><a href="#cite_note-2615b-24" title=""><span>[</span>25<span>]</span></a></sup></p>
<p>Summing up the existing evidence, a review in Prescrire International recommends pelvic floor exercises, which are "risk-free and effective in two-thirds to three-quarters of cases", as the first line treatment of SUI. Duloxetine use reduced the frequency of stress incontinence by one episode a day as compared with placebo. "The tangible effect of duloxetine on the quality of life is doubtful, with a maximum gain of five points on a 100-point scale." The review notes that, at best, duloxetine efficacy is "modest and transient, while its adverse effects are numerous and potentially severe."<sup id="cite_ref-pmid16400743_0-1" class="reference"><a href="#cite_note-pmid16400743-0" title=""><span>[</span>1<span>]</span></a></sup></p>
<p><a name="Painful_peripheral_neuropathy" id="Painful_peripheral_neuropathy"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Duloxetine&amp;action=edit&amp;section=5" title="Edit section: Painful peripheral neuropathy">edit</a>]</span> <span class="mw-headline">Painful peripheral neuropathy</span></h3>
<table class="metadata plainlinks ambox ambox-notice" style="">
<tr>
<td class="mbox-image">
<div style="width: 52px;"><a href="/wiki/File:Wiki_letter_w.svg" class="image" title="Wiki letter w.svg"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/6/6c/Wiki_letter_w.svg/44px-Wiki_letter_w.svg.png" width="44" height="44" border="0" /></a></div>
</td>
<td class="mbox-text" style=""><b>Please help <a href="http://en.wikipedia.org/w/index.php?title=Duloxetine&amp;action=edit" class="external text" title="http://en.wikipedia.org/w/index.php?title=Duloxetine&amp;action=edit" rel="nofollow">improve this article or section</a> by expanding it.</b> Further information might be found on the <a href="/wiki/Talk:Duloxetine" title="Talk:Duloxetine">talk page</a>. <small><i>(May 2008)</i></small></td>
</tr>
</table>
<p>At 20&#160;mg per day Cymbalta showed no clinical improvement over placebo. At 60&#160;mg per day Cymbalta showed modest improvement for diabetic pain over baseline, with 51% of patients treated with Cymbalta reporting at least a 30% sustained reduction in pain. In comparison, 31% of patients treated with placebo reported this magnitude of sustained pain reduction. In one study Duloxetine treatment was considered to be safe and well tolerated with less than 20 percent discontinuation due to adverse events, another trial had a low dropout rate of 12.1 percent.<sup id="cite_ref-25" class="reference"><a href="#cite_note-25" title=""><span>[</span>26<span>]</span></a></sup><sup id="cite_ref-26" class="reference"><a href="#cite_note-26" title=""><span>[</span>27<span>]</span></a></sup> Duloxetine is not effective for the numbness or tingling, nor is it effective for the other <a href="/wiki/Diabetes_mellitus" title="Diabetes mellitus">complications of diabetes</a>. It does not treat the underlying nerve damage, but can help reduce the pain.<sup id="cite_ref-27" class="reference"><a href="#cite_note-27" title=""><span>[</span>28<span>]</span></a></sup></p>
<p><a name="Generalized_anxiety_disorder" id="Generalized_anxiety_disorder"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Duloxetine&amp;action=edit&amp;section=6" title="Edit section: Generalized anxiety disorder">edit</a>]</span> <span class="mw-headline">Generalized anxiety disorder</span></h3>
<p>On May 11 2006, Eli Lilly and Company announced the recent submission of a supplemental New Drug Application (sNDA) to the U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration" class="mw-redirect">Food and Drug Administration</a> (FDA) for Cymbalta for the treatment of <a href="/wiki/Generalized_anxiety_disorder" title="Generalized anxiety disorder">generalized anxiety disorder</a> (GAD).</p>
<p>Eli Lilly said the FDA has approved Cymbalta for the treatment of GAD in February 2007.<sup id="cite_ref-28" class="reference"><a href="#cite_note-28" title=""><span>[</span>29<span>]</span></a></sup> Eli Lilly said that in clinical trials patients treated with Cymbalta for GAD experienced a 46% improvement in anxiety symptoms, compared to 32% for those who took placebo, as measured by the Hamilton Anxiety Scale.</p>
<p><a name="Fibromyalgia" id="Fibromyalgia"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Duloxetine&amp;action=edit&amp;section=7" title="Edit section: Fibromyalgia">edit</a>]</span> <span class="mw-headline">Fibromyalgia</span></h3>
<p>On <span class="mw-formatted-date" title="2006-10-19"><span class="mw-formatted-date" title="10-19"><a href="/wiki/October_19" title="October 19">October 19</a></span>, <a href="/wiki/2006" title="2006">2006</a></span>, Eli Lilly issued a press release saying they had done trials which found that Cymbalta, at 60&#160;mg once or twice daily, significantly reduced pain in more than half of women treated for <a href="/wiki/Fibromyalgia" title="Fibromyalgia">fibromyalgia</a> (FM), with and without major depression, according to 12-week data presented at the annual meeting of the <a href="/wiki/American_College_of_Rheumatology" title="American College of Rheumatology">American College of Rheumatology</a>. Eli Lilly is in Phase III of its FM trials and is expected to submit a sNDA to the FDA for approval of Cymbalta for FM within the next 12 months.</p>
<p>Critics argue that randomized controlled trials of FM are difficult due to factors such as a lack of understanding of the <a href="/wiki/Pathophysiology" title="Pathophysiology">pathophysiology</a> and a heterogeneous FM patient population. Although there is a lack of understanding of what causes FM, it is estimated that approximately 5-7% of the U.S. population has FM,<sup id="cite_ref-29" class="reference"><a href="#cite_note-29" title=""><span>[</span>30<span>]</span></a></sup> representing a large patient clientele. Eli Lilly hopes Cymbalta will be the first FDA approved medication for FM and had been promoting Cymbalta for FM since 2004.<sup id="cite_ref-Arnold2004_30-0" class="reference"><a href="#cite_note-Arnold2004-30" title=""><span>[</span>31<span>]</span></a></sup></p>
<p>In the study testing the efficacy of Cymbalta for FM, participants completed several questionnaires to measure the amount of pain and discomfort the disease caused them at the beginning of the study, and then at the end of each of the first two weeks and every second week for the remaining 12 weeks of the study. Researchers also tested the participants for depression.<sup id="cite_ref-Arnold2004_30-1" class="reference"><a href="#cite_note-Arnold2004-30" title=""><span>[</span>31<span>]</span></a></sup></p>
<p>Women who took Cymbalta had significantly less pain and discomfort than those who took the placebo. For men, who made up only 11% of the study, there was no effect from taking the medication compared with a placebo. Reportedly, depression played no part in whether or not the drug worked to control pain. The change in the level of women's pain was particularly pronounced after a month of taking the drug, then leveled off a bit before dropping again near the end of the study.<sup id="cite_ref-Arnold2004_30-2" class="reference"><a href="#cite_note-Arnold2004-30" title=""><span>[</span>31<span>]</span></a></sup></p>
<p>However, in one of the primary measures of pain there was no significant difference between the two groups at the end of the 12-week trial. Also, because the trial lasted only 12 weeks, it is impossible to tell how well the drug would control treatment for a longer period of time.<sup id="cite_ref-Arnold2004_30-3" class="reference"><a href="#cite_note-Arnold2004-30" title=""><span>[</span>31<span>]</span></a></sup></p>
<p>The Food and Drug Administration regulators approved the drug for the treatment of fibromyalgia in June 2008. <sup id="cite_ref-31" class="reference"><a href="#cite_note-31" title=""><span>[</span>32<span>]</span></a></sup></p>
<p><a name="Chronic_fatigue_syndrome" id="Chronic_fatigue_syndrome"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Duloxetine&amp;action=edit&amp;section=8" title="Edit section: Chronic fatigue syndrome">edit</a>]</span> <span class="mw-headline">Chronic fatigue syndrome</span></h3>
<p>As of January 11 2007, Eli Lilly is currently enrolling patients for <a href="/wiki/Double-blind" title="Double-blind" class="mw-redirect">double blind</a> Phase II and Phase III trials of Cymbalta for the use of <a href="/wiki/Chronic_Fatigue_Syndrome" title="Chronic Fatigue Syndrome" class="mw-redirect">Chronic Fatigue Syndrome</a> (CFS) in conjunction with the <a href="/wiki/University_of_Cincinnati" title="University of Cincinnati">University of Cincinnati</a>.<sup id="cite_ref-32" class="reference"><a href="#cite_note-32" title=""><span>[</span>33<span>]</span></a></sup> CFS is characterized by severe disabling fatigue of at least six months' duration which cannot be fully explained by an identifiable <a href="/wiki/Disease" title="Disease">medical condition</a>. Eli Lilly has not publicly stated their hypothesis for use of Cymbalta for CFS.<sup class="noprint Template-Fact"><span title="This claim needs references to reliable sources&#160;since May 2007" style="white-space: nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed">citation needed</a></i>]</span></sup></p>
<p><a name="Contraindications" id="Contraindications"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Duloxetine&amp;action=edit&amp;section=9" title="Edit section: Contraindications">edit</a>]</span> <span class="mw-headline">Contraindications</span></h2>
<p>The following contraindications are listed by the manufacturer:<sup class="noprint Template-Fact"><span title="This claim needs references to reliable sources&#160;since May 2008" style="white-space: nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed">citation needed</a></i>]</span></sup></p>
<ul>
<li>Hypersensitivity - duloxetine is contraindicated in patients with a known hypersensitivity to duloxetine or any of the inactive ingredients.</li>
<li><a href="/wiki/Monoamine_oxidase_inhibitor" title="Monoamine oxidase inhibitor">MAOIs</a> - concomitant use in patients taking <a href="/wiki/Monoamine_oxidase_inhibitor" title="Monoamine oxidase inhibitor">MAOIs</a> is contraindicated.</li>
<li>Uncontrolled narrow-angle <a href="/wiki/Glaucoma" title="Glaucoma">glaucoma</a> - in clinical trials, Cymbalta use was associated with an increased risk of <a href="/wiki/Mydriasis" title="Mydriasis">mydriasis</a> (dilation of the pupil); therefore, its use should be avoided in patients with uncontrolled narrow-angle <a href="/wiki/Glaucoma" title="Glaucoma">glaucoma</a>, in which mydriasis can cause sudden worsening.</li>
<li>CNS acting drugs - given the primary <a href="/wiki/Central_nervous_system" title="Central nervous system">central nervous system</a> (CNS) effects of duloxetine, it should be used with caution when it is taken in combination with or substituted for other centrally acting drugs, including those with a similar mechanism of action.</li>
<li>Cymbalta and <a href="/wiki/Thioridazine" title="Thioridazine">thioridazine</a> should not be co-administered.</li>
</ul>
<p><a name="Adverse_effects" id="Adverse_effects"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Duloxetine&amp;action=edit&amp;section=10" title="Edit section: Adverse effects">edit</a>]</span> <span class="mw-headline">Adverse effects</span></h2>
<table class="metadata plainlinks ambox ambox-style" style="">
<tr>
<td class="mbox-image">
<div style="width: 52px;"><a href="/wiki/File:Ambox_style.png" class="image" title="Ambox style.png"><img alt="" src="http://upload.wikimedia.org/wikipedia/en/d/d6/Ambox_style.png" width="40" height="40" border="0" /></a></div>
</td>
<td class="mbox-text" style="">This article <b>is in a list format that may be better presented using <a href="/wiki/Prose" title="Prose">prose</a>.</b> You can help by converting this section to prose, if <a href="/wiki/Wikipedia:Embedded_list" title="Wikipedia:Embedded list">appropriate</a>. <a href="/wiki/Help:Editing" title="Help:Editing">Editing help</a> is available. <small><i>(May 2008)</i></small></td>
</tr>
</table>
<p><a href="/wiki/Nausea" title="Nausea">Nausea</a>, <a href="/wiki/Somnolence" title="Somnolence">somnolence</a>, <a href="/wiki/Insomnia" title="Insomnia">insomnia</a>, and <a href="/wiki/Dizziness" title="Dizziness">dizziness</a> are the main side effects, reported by about 10% to 20% of patients.<sup id="cite_ref-33" class="reference"><a href="#cite_note-33" title=""><span>[</span>34<span>]</span></a></sup></p>
<p>In a trial for mild major depressive disorder (MDD), the most commonly reported treatment-emergent adverse events among duloxetine-treated patients were <a href="/wiki/Nausea" title="Nausea">nausea</a> (34.7%), <a href="/wiki/Dry_mouth" title="Dry mouth" class="mw-redirect">dry mouth</a> (22.7%), <a href="/wiki/Headache" title="Headache">headache</a> (20.0%) and <a href="/wiki/Dizziness" title="Dizziness">dizziness</a> (18.7%), and except for <a href="/wiki/Headache" title="Headache">headache</a>, these were reported significantly more often than in the placebo group:<sup id="cite_ref-34" class="reference"><a href="#cite_note-34" title=""><span>[</span>35<span>]</span></a></sup></p>
<p>Other side-effects include:</p>
<ul>
<li><a href="/wiki/Orthostatic_hypotension" title="Orthostatic hypotension">Orthostatic hypotension</a></li>
<li><a href="/wiki/Fatigue_(physical)" title="Fatigue (physical)" class="mw-redirect">Fatigue</a></li>
<li>Vivid nightmares</li>
<li>Increased sweating</li>
<li>Decreased appetite and weight loss</li>
<li>Blurred vision</li>
<li><a href="/wiki/Paresthesia" title="Paresthesia">Paresthesia</a></li>
<li>Disturbances of the <a href="/wiki/Gastrointestinal_tract" title="Gastrointestinal tract">gastrointestinal tract</a>, such as nausea, constipation, diarrhea, indigestion, vomiting and profuse bleeding</li>
<li><a href="/wiki/Tremor" title="Tremor">Tremor</a></li>
<li><a href="/wiki/Anxiety" title="Anxiety">Anxiety</a>, <a href="/wiki/Nervousness" title="Nervousness" class="mw-redirect">nervousness</a>, <a href="/wiki/Agitation" title="Agitation">agitation</a></li>
<li><a href="/wiki/Palpitations" title="Palpitations" class="mw-redirect">Palpitations</a></li>
<li>Decreased <a href="/wiki/Libido" title="Libido">sex drive</a> or difficulty achieving orgasm</li>
<li><a href="/wiki/Impotence" title="Impotence" class="mw-redirect">Impotence</a> or <a href="/wiki/Delayed_ejaculation" title="Delayed ejaculation">delayed ejaculation</a></li>
<li><a href="/wiki/Hot_flashes" title="Hot flashes" class="mw-redirect">Hot flashes</a></li>
<li>Taste disturbances</li>
<li>Difficulty passing urine</li>
<li>Increase in blood pressure or heart rate</li>
<li>Cold hands or feet</li>
<li><a href="/wiki/Jaundice" title="Jaundice">Jaundice</a></li>
<li>Inflammation of the liver or <a href="/wiki/Hepatitis" title="Hepatitis">hepatitis</a> leading to <a href="/wiki/Cirrhosis" title="Cirrhosis">cirrhosis</a> if left unchecked.</li>
<li><a href="/wiki/Depersonalization" title="Depersonalization">Depersonalization</a></li>
<li><a href="/wiki/Hypomania" title="Hypomania">Hypomania</a></li>
<li><a href="/wiki/Obesity" title="Obesity">Weight gain</a> or loss</li>
</ul>
<p>Duloxetine and SSRIs have been shown to cause sexual side effects in some patients, both males and females. Although usually reversible, these sexual side effects can sometimes last for months, years, or longer, even after the drug has been completely withdrawn.<sup class="noprint Template-Fact"><span title="This claim needs references to reliable sources&#160;since September 2007" style="white-space: nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed">citation needed</a></i>]</span></sup> This disorder is known as <a href="/wiki/Post-SSRI_sexual_dysfunction" title="Post-SSRI sexual dysfunction">post-SSRI sexual dysfunction</a>.</p>
<p><a name="Postmarketing_spontaneous_reports" id="Postmarketing_spontaneous_reports"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Duloxetine&amp;action=edit&amp;section=11" title="Edit section: Postmarketing spontaneous reports">edit</a>]</span> <span class="mw-headline">Postmarketing spontaneous reports</span></h3>
<p>Reported adverse events which were temporally correlated to Cymbalta therapy include rash, reported rarely, and the following adverse events, reported very rarely: <a href="/wiki/Alanine_aminotransferase" title="Alanine aminotransferase" class="mw-redirect">alanine aminotransferase</a> increased, <a href="/wiki/Alkaline_phosphatase" title="Alkaline phosphatase">alkaline phosphatase</a> increased, <a href="/wiki/Anaphylactic" title="Anaphylactic" class="mw-redirect">anaphylactic</a> reaction, <a href="/wiki/Angioneurotic_edema" title="Angioneurotic edema" class="mw-redirect">angioneurotic edema</a>, <a href="/wiki/Aspartate_aminotransferase" title="Aspartate aminotransferase" class="mw-redirect">aspartate aminotransferase</a> increased, <a href="/wiki/Bilirubin" title="Bilirubin">bilirubin</a> increased, <a href="/wiki/Glaucoma" title="Glaucoma">glaucoma</a>, <a href="/wiki/Hepatitis" title="Hepatitis">hepatitis</a>, <a href="/wiki/Hyponatremia" title="Hyponatremia">hyponatremia</a>, <a href="/wiki/Jaundice" title="Jaundice">jaundice</a>, <a href="/wiki/Orthostatic_hypotension" title="Orthostatic hypotension">orthostatic hypotension</a> (especially at the initiation of treatment), <a href="/wiki/Stevens-Johnson_syndrome" title="Stevens-Johnson syndrome">Stevens-Johnson syndrome</a>, <a href="/wiki/Syncope_(medicine)" title="Syncope (medicine)">syncope</a> (especially at initiation of treatment), and <a href="/wiki/Urticaria" title="Urticaria">urticaria</a>.<sup id="cite_ref-35" class="reference"><a href="#cite_note-35" title=""><span>[</span>36<span>]</span></a></sup></p>
<p>A number of more serious complications, in which duloxetine may have played a role, has been published in the form of case reports:</p>
<ul>
<li>The <a href="/wiki/Los_Angeles_County,_California" title="Los Angeles County, California">Los Angeles County</a> Department of Coroner released a report of the first <i><a href="/wiki/Post-mortem_examination" title="Post-mortem examination" class="mw-redirect">post mortem</a></i> studies of duloxetine; they identified twelve cases in which duloxetine was present on toxicologic analysis, but in no case was it deemed to be the ultimate cause of death. Five cases were declared multiple drug intoxication, and two were declared suicide.<sup id="cite_ref-36" class="reference"><a href="#cite_note-36" title=""><span>[</span>37<span>]</span></a></sup></li>
<li>A case of <a href="/wiki/Hyponatremia" title="Hyponatremia">hyponatremia</a> induced by duloxetine was reported by doctors at <a href="/wiki/Weill_Cornell_Medical_College_of_Cornell_University" title="Weill Cornell Medical College of Cornell University">Weill Cornell Medical College</a> in New York. This is common to all SSRIs.<sup id="cite_ref-37" class="reference"><a href="#cite_note-37" title=""><span>[</span>38<span>]</span></a></sup></li>
<li>A case of <a href="/wiki/Dyskinesia" title="Dyskinesia">dyskinesia</a> during treatment with duloxetine was reported in Germany.<sup id="cite_ref-38" class="reference"><a href="#cite_note-38" title=""><span>[</span>39<span>]</span></a></sup></li>
<li>Two episodes of <a href="/wiki/Serotonin_syndrome" title="Serotonin syndrome">serotonin syndrome</a> have been documented in the use of duloxetine in conjunction with other medications.<sup id="cite_ref-39" class="reference"><a href="#cite_note-39" title=""><span>[</span>40<span>]</span></a></sup><sup id="cite_ref-40" class="reference"><a href="#cite_note-40" title=""><span>[</span>41<span>]</span></a></sup></li>
<li>A case of <a href="/wiki/Fulminant_hepatic_failure" title="Fulminant hepatic failure" class="mw-redirect">fulminant hepatic failure</a> involving duloxetine which resulted in death was reported by the Department of Internal Medicine, <a href="/wiki/Ohio_State_University" title="Ohio State University">Ohio State University</a>, <a href="/wiki/Columbus,_Ohio" title="Columbus, Ohio">Columbus, Ohio</a>.<sup id="cite_ref-41" class="reference"><a href="#cite_note-41" title=""><span>[</span>42<span>]</span></a></sup></li>
<li>An attack of acute <a href="/wiki/Porphyria" title="Porphyria">porphyria</a> in a patient with known <a href="/wiki/Variegate_porphyria" title="Variegate porphyria">variegate porphyria</a> who had been commenced on duloxetine.<sup id="cite_ref-42" class="reference"><a href="#cite_note-42" title=""><span>[</span>43<span>]</span></a></sup></li>
</ul>
<p><a name="Discontinuation_syndrome" id="Discontinuation_syndrome"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Duloxetine&amp;action=edit&amp;section=12" title="Edit section: Discontinuation syndrome">edit</a>]</span> <span class="mw-headline">Discontinuation syndrome</span></h3>
<div class="rellink">Further information: <a href="/wiki/SSRI_discontinuation_syndrome" title="SSRI discontinuation syndrome">SSRI discontinuation syndrome</a></div>
<p>During marketing of other SSRIs and SNRIs, there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: <a href="/wiki/Dysphoria" title="Dysphoria">dysphoric mood</a>, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, <a href="/wiki/Labile_affect" title="Labile affect">emotional lability</a>, insomnia, hypomania, tinnitus, and seizures. Although these events are generally <a href="/wiki/Self-limiting" title="Self-limiting">self-limiting</a>, some have been reported to be severe. The <a href="/wiki/Withdrawal" title="Withdrawal">withdrawal</a> syndrome from duloxetine resembles the <a href="/wiki/SSRI_discontinuation_syndrome" title="SSRI discontinuation syndrome">SSRI discontinuation syndrome</a>.</p>
<p>When discontinuing treatment with Cymbalta, the manufacturer recommends a gradual reduction in the dose, rather than abrupt cessation, whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate."<sup id="cite_ref-43" class="reference"><a href="#cite_note-43" title=""><span>[</span>44<span>]</span></a></sup> This tapering process may be ineffective for some patients.<sup class="noprint Template-Fact"><span title="This claim needs references to reliable sources&#160;since May 2008" style="white-space: nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed">citation needed</a></i>]</span></sup></p>
<p>In MDD placebo-controlled clinical trials of up to nine weeks' duration, systematically evaluating discontinuation symptoms in patients taking duloxetine following abrupt discontinuation found the following symptoms occurring at a rate greater than or equal to 2% and at a significantly higher rate in Cymbalta-treated patients compared to those discontinuing from placebo: dizziness, nausea, headache, paresthesia, vomiting, irritability, and nightmare.<sup id="cite_ref-44" class="reference"><a href="#cite_note-44" title=""><span>[</span>45<span>]</span></a></sup></p>
<p><a name="Suicidality" id="Suicidality"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Duloxetine&amp;action=edit&amp;section=13" title="Edit section: Suicidality">edit</a>]</span> <span class="mw-headline">Suicidality</span></h3>
<p>The FDA requires all antidepressants, including duloxetine, to carry a <a href="/wiki/Black_box_warning" title="Black box warning">black box warning</a> stating that antidepressants may increase the risk of suicide in persons younger than 25. This warning is based on statistical analyses conducted by two independent groups of the FDA experts that found a 2-fold increase of the suicidal ideation and behavior in children and adolescents, and 1.5-fold increase of suicidality in the 18–24 age group.<sup id="cite_ref-FDA_45-0" class="reference"><a href="#cite_note-FDA-45" title=""><span>[</span>46<span>]</span></a></sup><sup id="cite_ref-FDA2_46-0" class="reference"><a href="#cite_note-FDA2-46" title=""><span>[</span>47<span>]</span></a></sup><sup id="cite_ref-FDA3_47-0" class="reference"><a href="#cite_note-FDA3-47" title=""><span>[</span>48<span>]</span></a></sup></p>
<p>To obtain <a href="/wiki/Statistically_significant" title="Statistically significant" class="mw-redirect">statistically significant</a> results the FDA had to combine the results of 295 trials of 11 antidepressants for psychiatric indications. As <a href="/wiki/Suicidal_ideation" title="Suicidal ideation">suicidal ideation</a> and behavior in clinical trials are rare, the results for any drug taken separately usually do not reach statistical significance. In line with the general results, duloxetine use in depressed adults insignificantly decreased the odds of suicidality by 12%<sup id="cite_ref-FDA2_46-1" class="reference"><a href="#cite_note-FDA2-46" title=""><span>[</span>47<span>]</span></a></sup> or 20%<sup id="cite_ref-FDA3_47-1" class="reference"><a href="#cite_note-FDA3-47" title=""><span>[</span>48<span>]</span></a></sup> depending of the statistical technique used. However, in the subgroup of young adults (18–24 years old) duloxetine increased the odds of suicidality 5-fold, close to statistical significance.<sup id="cite_ref-FDA2_46-2" class="reference"><a href="#cite_note-FDA2-46" title=""><span>[</span>47<span>]</span></a></sup> There have been no trials of duloxetine in minors.</p>
<p>Several commentators noted that the data FDA used in their analysis of duloxetine-associated suicidality may have been incomplete. According to Arif Khan, the Summary Basis of Approval used by the FDA to approve duloxetine for depression contained only the mention of two completed suicides out of 3490 patients, and the rest of the data was not sufficient to "conduct any meaningful analysis."<sup id="cite_ref-pmid17453659_48-0" class="reference"><a href="#cite_note-pmid17453659-48" title=""><span>[</span>49<span>]</span></a></sup> Jeanne Lenzer wrote in <a href="/wiki/The_Independent" title="The Independent">The Independent</a> and <a href="/wiki/Slate_(magazine)" title="Slate (magazine)">Slate Magazine</a>, and this fact was also confirmed by a Lilly spokesman, that another two completed suicides, which occurred in the depression studies ran by the Lilly's Japanese partner <a href="/wiki/Shionogi" title="Shionogi">Shionogi</a>, have not been reported to the FDA.<sup id="cite_ref-Slate_49-0" class="reference"><a href="#cite_note-Slate-49" title=""><span>[</span>50<span>]</span></a></sup><sup id="cite_ref-independent_50-0" class="reference"><a href="#cite_note-independent-50" title=""><span>[</span>51<span>]</span></a></sup> According to Lenzer, four completed suicides also occurred in the trials of duloxetine for stress urinary incontinence (SUI). As these trials failed, the FDA initially insisted that any information about them is a commercial secret and cannot be released.<sup id="cite_ref-independent_50-1" class="reference"><a href="#cite_note-independent-50" title=""><span>[</span>51<span>]</span></a></sup> Later, in a short statement the FDA acknowledged that in SUI trials eleven suicide attempts occurred in persons taking duloxetine vs none in the placebo group.<sup id="cite_ref-51" class="reference"><a href="#cite_note-51" title=""><span>[</span>52<span>]</span></a></sup></p>
<p>A series of four cases of duloxetine-associated suicidality has been reported. In all four cases depressed patients began having suicidal thoughts after starting on duloxetine or increasing its dose. These thoughts stopped, and the patients returned to normal after duloxetine was discontinued, and they were switched to another antidepressant.<sup id="cite_ref-52" class="reference"><a href="#cite_note-52" title=""><span>[</span>53<span>]</span></a></sup></p>
<p>A suicide of 19-year-old Traci Johnson, a healthy volunteer in a duloxetine <a href="/wiki/Clinical_pharmacology" title="Clinical pharmacology">clinical pharmacology</a> study, was highly publicized. For about a month she had been given high doses of duloxetine, and then she was switched to placebo. Four days after the switch, she hanged herself with her scarf from a shower rod in the bathroom of Lilly Laboratory for Clinical Research.<sup id="cite_ref-53" class="reference"><a href="#cite_note-53" title=""><span>[</span>54<span>]</span></a></sup><sup id="cite_ref-NYT_54-0" class="reference"><a href="#cite_note-NYT-54" title=""><span>[</span>55<span>]</span></a></sup> The <a href="/wiki/New_York_Times" title="New York Times" class="mw-redirect">New York Times</a> article mentioned a withdrawal syndrome as a possible reason for this suicide.<sup id="cite_ref-NYT_54-1" class="reference"><a href="#cite_note-NYT-54" title=""><span>[</span>55<span>]</span></a></sup></p>
<p><a name="Pharmacology" id="Pharmacology"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Duloxetine&amp;action=edit&amp;section=14" title="Edit section: Pharmacology">edit</a>]</span> <span class="mw-headline">Pharmacology</span></h2>
<p><b>Pharmacodynamics</b></p>
<p>Although the exact mechanisms of the antidepressant and central pain inhibitory action of duloxetine in humans are unknown, they are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS. Preclinical studies demonstrate that duloxetine potently inhibits neuronal serotonin and norepinephrine reuptake <sup id="cite_ref-55" class="reference"><a href="#cite_note-55" title=""><span>[</span>56<span>]</span></a></sup>, and it has been demonstrated that this inhibition is balanced throughout the dosing range (when compared to venlafaxine in which the inhibition of noradrenaline is low at low doses and raises as the dose escalates).</p>
<p>It is also considered a less potent inhibitor of dopamine reuptake. However, duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors and can therefore be considered to be a selective reuptake inhibitor at the 5-HT and NA receptors. Duloxetine undergoes extensive <a href="/wiki/Metabolism" title="Metabolism">metabolism</a>, but the major circulating metabolites do not contribute significantly to the pharmacologic activity.</p>
<p><b>Pharmacokinetics</b></p>
<p>Duloxetine has an <a href="/wiki/Elimination_half-life" title="Elimination half-life" class="mw-redirect">elimination half-life</a> of about 12 hours (range 8 to 17 hours) and its pharmacokinetics are dose proportional over the <a href="/wiki/Therapeutic_index" title="Therapeutic index">therapeutic range</a>. Steady-state is usually achieved after 3 days.</p>
<p>Elimination of duloxetine is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP1A2.</p>
<p>When orally administered it is well absorbed. There is an average 2-hour lag until absorption begins with maximal plasma concentrations occurring about 6 hours post dose. Food does not affect the C<sub>max</sub> of duloxetine, but delays the time to reach peak concentration from 6 to 10 hours. Duloxetine is highly bound (&gt;90%) to proteins in human plasma, binding primarily to albumin and α1-acid glycoprotein.</p>
<p>Metabolism and Elimination — Only trace amounts (&lt;1%) of unchanged duloxetine are present in the urine and most of the dose (aprox 70%) appears in the urine as metabolites of duloxetine with about 20% excreted in the feces.</p>
<p><a name="See_also" id="See_also"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Duloxetine&amp;action=edit&amp;section=15" title="Edit section: See also">edit</a>]</span> <span class="mw-headline">See also</span></h2>
<ul>
<li><a href="/wiki/Serotonin-norepinephrine_reuptake_inhibitor" title="Serotonin-norepinephrine reuptake inhibitor">Serotonin-norepinephrine reuptake inhibitor</a> (SNRI)</li>
<li><a href="/wiki/Neuropsychopharmacology" title="Neuropsychopharmacology">Neuropsychopharmacology</a></li>
<li><a href="/wiki/Neuropharmacology" title="Neuropharmacology">Neuropharmacology</a></li>
<li><a href="/wiki/Pharmacology" title="Pharmacology">Pharmacology</a></li>
<li><a href="/wiki/Psychoactive_drug" title="Psychoactive drug">Psychoactive drug</a></li>
</ul>
<p><a name="References" id="References"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Duloxetine&amp;action=edit&amp;section=16" title="Edit section: References">edit</a>]</span> <span class="mw-headline">References</span></h2>
<div class="references-small references-column-count references-column-count-2" style="-moz-column-count:2; column-count:2;">
<ol class="references">
<li id="cite_note-pmid16400743-0">^ <a href="#cite_ref-pmid16400743_0-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid16400743_0-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="">"Duloxetine: new drug. For stress urinary incontinence: too much risk, too little benefit". <i>Prescrire Int</i> <b>14</b> (80): 218–20. December 2005. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16400743" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16400743">PMID 16400743</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Duloxetine%3A+new+drug.+For+stress+urinary+incontinence%3A+too+much+risk%2C+too+little+benefit&amp;rft.jtitle=Prescrire+Int&amp;rft.date=December+2005&amp;rft.volume=14&amp;rft.issue=80&amp;rft.pages=218%E2%80%9320&amp;rft_id=info:pmid/16400743&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid17121211-1">^ <a href="#cite_ref-pmid17121211_1-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid17121211_1-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="">"Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects". <i>Prescrire Int</i> <b>15</b> (85): 168–72. October 2006. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17121211" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17121211">PMID 17121211</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Duloxetine%3A+new+indication.+Depression+and+diabetic+neuropathy%3A+too+many+adverse+effects&amp;rft.jtitle=Prescrire+Int&amp;rft.date=October+2006&amp;rft.volume=15&amp;rft.issue=85&amp;rft.pages=168%E2%80%9372&amp;rft_id=info:pmid/17121211&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid17451072-2"><b><a href="#cite_ref-pmid17451072_2-0" title="">^</a></b> Drug and Therapeutics Bulletin concurs: "There is insufficient published evidence of its comparative efficacy to judge its duloxetine place in depression among many other longer-established antidepressant drugs, or how it compares with other therapy for diabetic peripheral neuropathic pain. Therefore we can see no place for it in either indication." <cite style="font-style:normal" class="">"<a href="http://dtb.bmj.com/cgi/pmidlookup?view=long&amp;pmid=17451072" class="external text" title="http://dtb.bmj.com/cgi/pmidlookup?view=long&amp;pmid=17451072" rel="nofollow">Is there a place for duloxetine?</a>". <i>Drug Ther Bull</i> <b>45</b> (4): 29–32. April 2007. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1136%2Fdtb.2007.45429" class="external text" title="http://dx.doi.org/10.1136%2Fdtb.2007.45429" rel="nofollow">10.1136/dtb.2007.45429</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17451072" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17451072">PMID 17451072</a><span class="printonly">. <a href="http://dtb.bmj.com/cgi/pmidlookup?view=long&amp;pmid=17451072" class="external free" title="http://dtb.bmj.com/cgi/pmidlookup?view=long&amp;pmid=17451072" rel="nofollow">http://dtb.bmj.com/cgi/pmidlookup?view=long&amp;pmid=17451072</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Is+there+a+place+for+duloxetine%3F&amp;rft.jtitle=Drug+Ther+Bull&amp;rft.date=April+2007&amp;rft.volume=45&amp;rft.issue=4&amp;rft.pages=29%E2%80%9332&amp;rft_id=info:doi/10.1136%2Fdtb.2007.45429&amp;rft_id=info:pmid/17451072&amp;rft_id=http%3A%2F%2Fdtb.bmj.com%2Fcgi%2Fpmidlookup%3Fview%3Dlong%26pmid%3D17451072&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-United_States_Patent:_4956388-3"><b><a href="#cite_ref-United_States_Patent:_4956388_3-0" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREFRobertson_DW.2C_Wong_DT.2C_Krushinski_JH1990">Robertson DW, Wong DT, Krushinski JH (1990-09-11). <a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITOFF&amp;d=PALL&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&amp;r=1&amp;f=G&amp;l=50&amp;s1=4956388.PN.&amp;OS=PN/4956388&amp;RS=PN/4956388" class="external text" title="http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITOFF&amp;d=PALL&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&amp;r=1&amp;f=G&amp;l=50&amp;s1=4956388.PN.&amp;OS=PN/4956388&amp;RS=PN/4956388" rel="nofollow">"United States Patent 4,956,388: 3-Aryloxy-3-substituted propanamines"</a> (htm). USPTO<span class="printonly">. <a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITOFF&amp;d=PALL&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&amp;r=1&amp;f=G&amp;l=50&amp;s1=4956388.PN.&amp;OS=PN/4956388&amp;RS=PN/4956388" class="external free" title="http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITOFF&amp;d=PALL&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&amp;r=1&amp;f=G&amp;l=50&amp;s1=4956388.PN.&amp;OS=PN/4956388&amp;RS=PN/4956388" rel="nofollow">http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITOFF&amp;d=PALL&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&amp;r=1&amp;f=G&amp;l=50&amp;s1=4956388.PN.&amp;OS=PN/4956388&amp;RS=PN/4956388</a></span><span class="reference-accessdate">. Retrieved on 2008-05-17</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=United+States+Patent+4%2C956%2C388%3A++3-Aryloxy-3-substituted+propanamines&amp;rft.atitle=&amp;rft.aulast=Robertson+DW%2C+Wong+DT%2C+Krushinski+JH&amp;rft.au=Robertson+DW%2C+Wong+DT%2C+Krushinski+JH&amp;rft.date=1990-09-11&amp;rft.pub=USPTO&amp;rft_id=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO1%26Sect2%3DHITOFF%26d%3DPALL%26p%3D1%26u%3D%252Fnetahtml%252FPTO%252Fsrchnum.htm%26r%3D1%26f%3DG%26l%3D50%26s1%3D4956388.PN.%26OS%3DPN%2F4956388%26RS%3DPN%2F4956388&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-4"><b><a href="#cite_ref-4" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFWong_DT.2C_Robertson_DW.2C_Bymaster_FP.2C_Krushinski_JH.2C_Reid_LR1988">Wong DT, Robertson DW, Bymaster FP, Krushinski JH, Reid LR (1988). "LY227942, an inhibitor of serotonin and norepinephrine uptake: biochemical pharmacology of a potential antidepressant drug". <i>Life Sci.</i> <b>43</b> (24): 2049–57. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2F0024-3205%2888%2990579-6" class="external text" title="http://dx.doi.org/10.1016%2F0024-3205%2888%2990579-6" rel="nofollow">10.1016/0024-3205(88)90579-6</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2850421" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/2850421">PMID 2850421</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=LY227942%2C+an+inhibitor+of+serotonin+and+norepinephrine+uptake%3A+biochemical+pharmacology+of+a+potential+antidepressant+drug&amp;rft.jtitle=Life+Sci.&amp;rft.aulast=Wong+DT%2C+Robertson+DW%2C+Bymaster+FP%2C+Krushinski+JH%2C+Reid+LR&amp;rft.au=Wong+DT%2C+Robertson+DW%2C+Bymaster+FP%2C+Krushinski+JH%2C+Reid+LR&amp;rft.date=1988&amp;rft.volume=43&amp;rft.issue=24&amp;rft.pages=2049%E2%80%9357&amp;rft_id=info:doi/10.1016%2F0024-3205%2888%2990579-6&amp;rft_id=info:pmid/2850421&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid14643350-5"><b><a href="#cite_ref-pmid14643350_5-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFBymaster_FP.2C_Beedle_EE.2C_Findlay_J.2C_.27.27et_al.27.272003">Bymaster FP, Beedle EE, Findlay J, <i>et al</i> (December 2003). "<a href="http://linkinghub.elsevier.com/retrieve/pii/S0960894X03010072" class="external text" title="http://linkinghub.elsevier.com/retrieve/pii/S0960894X03010072" rel="nofollow">Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake</a>". <i>Bioorg. Med. Chem. Lett.</i> <b>13</b> (24): 4477–80. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2Fj.bmcl.2003.08.079" class="external text" title="http://dx.doi.org/10.1016%2Fj.bmcl.2003.08.079" rel="nofollow">10.1016/j.bmcl.2003.08.079</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14643350" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/14643350">PMID 14643350</a><span class="printonly">. <a href="http://linkinghub.elsevier.com/retrieve/pii/S0960894X03010072" class="external free" title="http://linkinghub.elsevier.com/retrieve/pii/S0960894X03010072" rel="nofollow">http://linkinghub.elsevier.com/retrieve/pii/S0960894X03010072</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Duloxetine+%28Cymbalta%29%2C+a+dual+inhibitor+of+serotonin+and+norepinephrine+reuptake&amp;rft.jtitle=Bioorg.+Med.+Chem.+Lett.&amp;rft.aulast=Bymaster+FP%2C+Beedle+EE%2C+Findlay+J%2C+%27%27et+al%27%27&amp;rft.au=Bymaster+FP%2C+Beedle+EE%2C+Findlay+J%2C+%27%27et+al%27%27&amp;rft.date=December+2003&amp;rft.volume=13&amp;rft.issue=24&amp;rft.pages=4477%E2%80%9380&amp;rft_id=info:doi/10.1016%2Fj.bmcl.2003.08.079&amp;rft_id=info:pmid/14643350&amp;rft_id=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0960894X03010072&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-6"><b><a href="#cite_ref-6" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFTurcotte_JE.2C_Debonnel_G.2C_de_Montigny_C.2C_H.C3.A9bert_C.2C_Blier_P2001">Turcotte JE, Debonnel G, de Montigny C, Hébert C, Blier P (May 2001). "<a href="http://www.nature.com/npp/journal/v24/n5/abs/1395628a.html" class="external text" title="http://www.nature.com/npp/journal/v24/n5/abs/1395628a.html" rel="nofollow">Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects</a>". <i>Neuropsychopharmacology</i> <b>24</b> (5): 511–21. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2FS0893-133X%2800%2900220-7" class="external text" title="http://dx.doi.org/10.1016%2FS0893-133X%2800%2900220-7" rel="nofollow">10.1016/S0893-133X(00)00220-7</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11282251" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11282251">PMID 11282251</a><span class="printonly">. <a href="http://www.nature.com/npp/journal/v24/n5/abs/1395628a.html" class="external free" title="http://www.nature.com/npp/journal/v24/n5/abs/1395628a.html" rel="nofollow">http://www.nature.com/npp/journal/v24/n5/abs/1395628a.html</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Assessment+of+the+serotonin+and+norepinephrine+reuptake+blocking+properties+of+duloxetine+in+healthy+subjects&amp;rft.jtitle=Neuropsychopharmacology&amp;rft.aulast=Turcotte+JE%2C+Debonnel+G%2C+de+Montigny+C%2C+H%C3%A9bert+C%2C+Blier+P&amp;rft.au=Turcotte+JE%2C+Debonnel+G%2C+de+Montigny+C%2C+H%C3%A9bert+C%2C+Blier+P&amp;rft.date=May+2001&amp;rft.volume=24&amp;rft.issue=5&amp;rft.pages=511%E2%80%9321&amp;rft_id=info:doi/10.1016%2FS0893-133X%2800%2900220-7&amp;rft_id=info:pmid/11282251&amp;rft_id=http%3A%2F%2Fwww.nature.com%2Fnpp%2Fjournal%2Fv24%2Fn5%2Fabs%2F1395628a.html&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid11926722-7"><b><a href="#cite_ref-pmid11926722_7-0" title="">^</a></b> For example, see: <cite style="font-style:normal" class="" id="CITEREFGoldstein_DJ.2C_Mallinckrodt_C.2C_Lu_Y.2C_Demitrack_MA2002">Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA (March 2002). "Duloxetine in the treatment a double-blind clinical trial". <i>J Clin Psychiatry</i> <b>63</b> (3): 225–31. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11926722" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11926722">PMID 11926722</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Duloxetine+in+the+treatment++a+double-blind+clinical+trial&amp;rft.jtitle=J+Clin+Psychiatry&amp;rft.aulast=Goldstein+DJ%2C+Mallinckrodt+C%2C+Lu+Y%2C+Demitrack+MA&amp;rft.au=Goldstein+DJ%2C+Mallinckrodt+C%2C+Lu+Y%2C+Demitrack+MA&amp;rft.date=March+2002&amp;rft.volume=63&amp;rft.issue=3&amp;rft.pages=225%E2%80%9331&amp;rft_id=info:pmid/11926722&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-reg_history-8"><b><a href="#cite_ref-reg_history_8-0" title="">^</a></b> <cite style="font-style:normal" class="web"><a href="http://www.fda.gov/cder/foi/nda/2004/021427_s000_Cymbalta_AdminCorres.pdf" class="external text" title="http://www.fda.gov/cder/foi/nda/2004/021427_s000_Cymbalta_AdminCorres.pdf" rel="nofollow">"Approval package for: application number NDA 721-427. Administrative/Correspondence #2"</a> (PDF). The FDA Center for Drug Evaluation and Research. 2003<span class="printonly">. <a href="http://www.fda.gov/cder/foi/nda/2004/021427_s000_Cymbalta_AdminCorres.pdf" class="external free" title="http://www.fda.gov/cder/foi/nda/2004/021427_s000_Cymbalta_AdminCorres.pdf" rel="nofollow">http://www.fda.gov/cder/foi/nda/2004/021427_s000_Cymbalta_AdminCorres.pdf</a></span><span class="reference-accessdate">. Retrieved on 2008-05-18</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Approval+package+for%3A+application+number+NDA+721-427.+Administrative%2FCorrespondence+%232&amp;rft.atitle=&amp;rft.date=2003&amp;rft.pub=The+FDA+Center+for+Drug+Evaluation+and+Research&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Fnda%2F2004%2F021427_s000_Cymbalta_AdminCorres.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-9"><b><a href="#cite_ref-9" title="">^</a></b> <a href="http://www.fda.gov/bbs/topics/news/2004/NEW01113.html" class="external text" title="http://www.fda.gov/bbs/topics/news/2004/NEW01113.html" rel="nofollow">FDA news</a></li>
<li id="cite_note-10"><b><a href="#cite_ref-10" title="">^</a></b> <a href="http://cpe0013211b4c6d-cm0014e88ee7a4.cpe.net.cable.rogers.com/NocWeb/viewnoce.jsp?noc=kjmd" class="external text" title="http://cpe0013211b4c6d-cm0014e88ee7a4.cpe.net.cable.rogers.com/NocWeb/viewnoce.jsp?noc=kjmd" rel="nofollow">Health Canada Notice of Compliance Database - duloxetine</a>. November 1, 2007, retrieved November 24, 2007.</li>
<li id="cite_note-Yentreve-11"><b><a href="#cite_ref-Yentreve_11-0" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREFSteyer_R2006">Steyer R (2006-02-15). <a href="http://www.thestreet.com/_googlen/stocks/pharmaceuticals/10268662.html?cm_ven=GOOGLEN&amp;cm_cat=FREE&amp;cm_ite=NA" class="external text" title="http://www.thestreet.com/_googlen/stocks/pharmaceuticals/10268662.html?cm_ven=GOOGLEN&amp;cm_cat=FREE&amp;cm_ite=NA" rel="nofollow">"Lilly Won't Pursue Yentreve for U.S."</a> (htm). TheStreet.com<span class="printonly">. <a href="http://www.thestreet.com/_googlen/stocks/pharmaceuticals/10268662.html?cm_ven=GOOGLEN&amp;cm_cat=FREE&amp;cm_ite=NA" class="external free" title="http://www.thestreet.com/_googlen/stocks/pharmaceuticals/10268662.html?cm_ven=GOOGLEN&amp;cm_cat=FREE&amp;cm_ite=NA" rel="nofollow">http://www.thestreet.com/_googlen/stocks/pharmaceuticals/10268662.html?cm_ven=GOOGLEN&amp;cm_cat=FREE&amp;cm_ite=NA</a></span><span class="reference-accessdate">. Retrieved on 2008-05-18</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Lilly+Won%27t+Pursue+Yentreve+for+U.S.&amp;rft.atitle=&amp;rft.aulast=Steyer+R&amp;rft.au=Steyer+R&amp;rft.date=2006-02-15&amp;rft.pub=TheStreet.com&amp;rft_id=http%3A%2F%2Fwww.thestreet.com%2F_googlen%2Fstocks%2Fpharmaceuticals%2F10268662.html%3Fcm_ven%3DGOOGLEN%26cm_cat%3DFREE%26cm_ite%3DNA&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-FDA-1-12"><b><a href="#cite_ref-FDA-1_12-0" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREFAndreason_PJ">Andreason PJ. <a href="http://www.fda.gov/cder/foi/nda/2004/021427_s000_Cymbalta_Medr_P1.pdf" class="external text" title="http://www.fda.gov/cder/foi/nda/2004/021427_s000_Cymbalta_Medr_P1.pdf" rel="nofollow">"Clinical review for NDA 21-427 Cymbalta (duloxetine)."</a> (PDF). <i>CDER approval package for application number 21-427. Medical review # 3.</i>. FDA. 12<span class="printonly">. <a href="http://www.fda.gov/cder/foi/nda/2004/021427_s000_Cymbalta_Medr_P1.pdf" class="external free" title="http://www.fda.gov/cder/foi/nda/2004/021427_s000_Cymbalta_Medr_P1.pdf" rel="nofollow">http://www.fda.gov/cder/foi/nda/2004/021427_s000_Cymbalta_Medr_P1.pdf</a></span><span class="reference-accessdate">. Retrieved on 2008-05-22</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Clinical+review+for+NDA+21-427+Cymbalta+%28duloxetine%29.&amp;rft.atitle=CDER+approval+package+for+application+number+21-427.+Medical+review+%23+3.&amp;rft.aulast=Andreason+PJ&amp;rft.au=Andreason+PJ&amp;rft.pages=12&amp;rft.pub=FDA&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Fnda%2F2004%2F021427_s000_Cymbalta_Medr_P1.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-13"><b><a href="#cite_ref-13" title="">^</a></b> <a href="http://ajp.psychiatryonline.org/cgi/content/abstract/164/6/900?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;fulltext=duloxetine&amp;searchid=1&amp;FIRSTINDEX=0&amp;sortspec=relevance&amp;resourcetype=HWCIT" class="external free" title="http://ajp.psychiatryonline.org/cgi/content/abstract/164/6/900?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;fulltext=duloxetine&amp;searchid=1&amp;FIRSTINDEX=0&amp;sortspec=relevance&amp;resourcetype=HWCIT" rel="nofollow">http://ajp.psychiatryonline.org/cgi/content/abstract/164/6/900?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;fulltext=duloxetine&amp;searchid=1&amp;FIRSTINDEX=0&amp;sortspec=relevance&amp;resourcetype=HWCIT</a></li>
<li id="cite_note-pmid18199864-14"><b><a href="#cite_ref-pmid18199864_14-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFTurner_EH.2C_Matthews_AM.2C_Linardatos_E.2C_Tell_RA.2C_Rosenthal_R2008">Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (January 2008). "Selective publication of antidepressant trials and its influence on apparent efficacy". <i>N. Engl. J. Med.</i> <b>358</b> (3): 252–60. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1056%2FNEJMsa065779" class="external text" title="http://dx.doi.org/10.1056%2FNEJMsa065779" rel="nofollow">10.1056/NEJMsa065779</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18199864" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/18199864">PMID 18199864</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Selective+publication+of+antidepressant+trials+and+its+influence+on+apparent+efficacy&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.aulast=Turner+EH%2C+Matthews+AM%2C+Linardatos+E%2C+Tell+RA%2C+Rosenthal+R&amp;rft.au=Turner+EH%2C+Matthews+AM%2C+Linardatos+E%2C+Tell+RA%2C+Rosenthal+R&amp;rft.date=January+2008&amp;rft.volume=358&amp;rft.issue=3&amp;rft.pages=252%E2%80%9360&amp;rft_id=info:doi/10.1056%2FNEJMsa065779&amp;rft_id=info:pmid/18199864&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid17588546-15"><b><a href="#cite_ref-pmid17588546_15-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFPapakostas_GI.2C_Thase_ME.2C_Fava_M.2C_Nelson_JC.2C_Shelton_RC2007">Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC (December 2007). "Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents". <i>Biol. Psychiatry</i> <b>62</b> (11): 1217–27. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2Fj.biopsych.2007.03.027" class="external text" title="http://dx.doi.org/10.1016%2Fj.biopsych.2007.03.027" rel="nofollow">10.1016/j.biopsych.2007.03.027</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17588546" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17588546">PMID 17588546</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Are+antidepressant+drugs+that+combine+serotonergic+and+noradrenergic+mechanisms+of+action+more+effective+than+the+selective+serotonin+reuptake+inhibitors+in+treating+major+depressive+disorder%3F+A+meta-analysis+of+studies+of+newer+agents&amp;rft.jtitle=Biol.+Psychiatry&amp;rft.aulast=Papakostas+GI%2C+Thase+ME%2C+Fava+M%2C+Nelson+JC%2C+Shelton+RC&amp;rft.au=Papakostas+GI%2C+Thase+ME%2C+Fava+M%2C+Nelson+JC%2C+Shelton+RC&amp;rft.date=December+2007&amp;rft.volume=62&amp;rft.issue=11&amp;rft.pages=1217%E2%80%9327&amp;rft_id=info:doi/10.1016%2Fj.biopsych.2007.03.027&amp;rft_id=info:pmid/17588546&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid18545055-16"><b><a href="#cite_ref-pmid18545055_16-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFLam_RW.2C_Andersen_HF.2C_Wade_AG2008">Lam RW, Andersen HF, Wade AG (July 2008). "Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials". <i>Int Clin Psychopharmacol</i> <b>23</b> (4): 181–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1097%2FYIC.0b013e3282ffdedc" class="external text" title="http://dx.doi.org/10.1097%2FYIC.0b013e3282ffdedc" rel="nofollow">10.1097/YIC.0b013e3282ffdedc</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18545055" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/18545055">PMID 18545055</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Escitalopram+and+duloxetine+in+the+treatment+of+major+depressive+disorder%3A+a+pooled+analysis+of+two+trials&amp;rft.jtitle=Int+Clin+Psychopharmacol&amp;rft.aulast=Lam+RW%2C+Andersen+HF%2C+Wade+AG&amp;rft.au=Lam+RW%2C+Andersen+HF%2C+Wade+AG&amp;rft.date=July+2008&amp;rft.volume=23&amp;rft.issue=4&amp;rft.pages=181%E2%80%937&amp;rft_id=info:doi/10.1097%2FYIC.0b013e3282ffdedc&amp;rft_id=info:pmid/18545055&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid19185342-17"><b><a href="#cite_ref-pmid19185342_17-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFCipriani_A.2C_Furukawa_TA.2C_Salanti_G.2C_.27.27et_al.27.272009">Cipriani A, Furukawa TA, Salanti G, <i>et al</i> (January 2009). "Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis". <i>Lancet</i> <b>373</b>: 746. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2FS0140-6736%2809%2960046-5" class="external text" title="http://dx.doi.org/10.1016%2FS0140-6736%2809%2960046-5" rel="nofollow">10.1016/S0140-6736(09)60046-5</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19185342" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/19185342">PMID 19185342</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Comparative+efficacy+and+acceptability+of+12+new-generation+antidepressants%3A+a+multiple-treatments+meta-analysis&amp;rft.jtitle=Lancet&amp;rft.aulast=Cipriani+A%2C+Furukawa+TA%2C+Salanti+G%2C+%27%27et+al%27%27&amp;rft.au=Cipriani+A%2C+Furukawa+TA%2C+Salanti+G%2C+%27%27et+al%27%27&amp;rft.date=January+2009&amp;rft.volume=373&amp;rft.pages=746&amp;rft_id=info:doi/10.1016%2FS0140-6736%2809%2960046-5&amp;rft_id=info:pmid/19185342&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-18"><b><a href="#cite_ref-18" title="">^</a></b> <cite style="font-style:normal" class="">"<a href="http://dtb.bmj.com/cgi/pmidlookup?view=long&amp;pmid=17451072" class="external text" title="http://dtb.bmj.com/cgi/pmidlookup?view=long&amp;pmid=17451072" rel="nofollow">Is there a place for duloxetine?</a>". <i>Drug Ther Bull</i> <b>45</b> (4): 29–32. April 2007. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1136%2Fdtb.2007.45429" class="external text" title="http://dx.doi.org/10.1136%2Fdtb.2007.45429" rel="nofollow">10.1136/dtb.2007.45429</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17451072" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17451072">PMID 17451072</a><span class="printonly">. <a href="http://dtb.bmj.com/cgi/pmidlookup?view=long&amp;pmid=17451072" class="external free" title="http://dtb.bmj.com/cgi/pmidlookup?view=long&amp;pmid=17451072" rel="nofollow">http://dtb.bmj.com/cgi/pmidlookup?view=long&amp;pmid=17451072</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Is+there+a+place+for+duloxetine%3F&amp;rft.jtitle=Drug+Ther+Bull&amp;rft.date=April+2007&amp;rft.volume=45&amp;rft.issue=4&amp;rft.pages=29%E2%80%9332&amp;rft_id=info:doi/10.1136%2Fdtb.2007.45429&amp;rft_id=info:pmid/17451072&amp;rft_id=http%3A%2F%2Fdtb.bmj.com%2Fcgi%2Fpmidlookup%3Fview%3Dlong%26pmid%3D17451072&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-19"><b><a href="#cite_ref-19" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFVoelker_R1998">Voelker R (September 1998). "<a href="http://jama.ama-assn.org/cgi/content/full/280/11/951" class="external text" title="http://jama.ama-assn.org/cgi/content/full/280/11/951" rel="nofollow">International group seeks to dispel incontinence "taboo"</a>". <i>JAMA</i> <b>280</b> (11): 951–3. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1001%2Fjama.280.11.951" class="external text" title="http://dx.doi.org/10.1001%2Fjama.280.11.951" rel="nofollow">10.1001/jama.280.11.951</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9749464" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9749464">PMID 9749464</a><span class="printonly">. <a href="http://jama.ama-assn.org/cgi/content/full/280/11/951" class="external free" title="http://jama.ama-assn.org/cgi/content/full/280/11/951" rel="nofollow">http://jama.ama-assn.org/cgi/content/full/280/11/951</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=International+group+seeks+to+dispel+incontinence+%22taboo%22&amp;rft.jtitle=JAMA&amp;rft.aulast=Voelker+R&amp;rft.au=Voelker+R&amp;rft.date=September+1998&amp;rft.volume=280&amp;rft.issue=11&amp;rft.pages=951%E2%80%933&amp;rft_id=info:doi/10.1001%2Fjama.280.11.951&amp;rft_id=info:pmid/9749464&amp;rft_id=http%3A%2F%2Fjama.ama-assn.org%2Fcgi%2Fcontent%2Ffull%2F280%2F11%2F951&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-cochrane-20">^ <a href="#cite_ref-cochrane_20-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-cochrane_20-1" title=""><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-cochrane_20-2" title=""><sup><i><b>c</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFMariappan_P.2C_Ballantyne_Z.2C_N.27Dow_JM.2C_Alhasso_AA2005">Mariappan P, Ballantyne Z, N'Dow JM, Alhasso AA (2005). "<a href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004742/frame.html" class="external text" title="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004742/frame.html" rel="nofollow">Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults</a>". <i>Cochrane Database Syst Rev</i> (3): CD004742. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1002%2F14651858.CD004742.pub2" class="external text" title="http://dx.doi.org/10.1002%2F14651858.CD004742.pub2" rel="nofollow">10.1002/14651858.CD004742.pub2</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16034945" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16034945">PMID 16034945</a><span class="printonly">. <a href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004742/frame.html" class="external free" title="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004742/frame.html" rel="nofollow">http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004742/frame.html</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Serotonin+and+noradrenaline+reuptake+inhibitors+%28SNRI%29+for+stress+urinary+incontinence+in+adults&amp;rft.jtitle=Cochrane+Database+Syst+Rev&amp;rft.aulast=Mariappan+P%2C+Ballantyne+Z%2C+N%27Dow+JM%2C+Alhasso+AA&amp;rft.au=Mariappan+P%2C+Ballantyne+Z%2C+N%27Dow+JM%2C+Alhasso+AA&amp;rft.date=2005&amp;rft.issue=3&amp;rft.pages=CD004742&amp;rft_id=info:doi/10.1002%2F14651858.CD004742.pub2&amp;rft_id=info:pmid/16034945&amp;rft_id=http%3A%2F%2Fwww.mrw.interscience.wiley.com%2Fcochrane%2Fclsysrev%2Farticles%2FCD004742%2Fframe.html&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-UM-21">^ <a href="#cite_ref-UM_21-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-UM_21-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFShamliyan_TA.2C_Kane_RL.2C_Wyman_J.2C_Wilt_TJ2008">Shamliyan TA, Kane RL, Wyman J, Wilt TJ (March 2008). "Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women". <i>Ann. Intern. Med.</i> <b>148</b> (6): 459–73. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18268288" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/18268288">PMID 18268288</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Systematic+review%3A+randomized%2C+controlled+trials+of+nonsurgical+treatments+for+urinary+incontinence+in+women&amp;rft.jtitle=Ann.+Intern.+Med.&amp;rft.aulast=Shamliyan+TA%2C+Kane+RL%2C+Wyman+J%2C+Wilt+TJ&amp;rft.au=Shamliyan+TA%2C+Kane+RL%2C+Wyman+J%2C+Wilt+TJ&amp;rft.date=March+2008&amp;rft.volume=148&amp;rft.issue=6&amp;rft.pages=459%E2%80%9373&amp;rft_id=info:pmid/18268288&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-ahrq-22">^ <a href="#cite_ref-ahrq_22-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-ahrq_22-1" title=""><sup><i><b>b</b></i></sup></a> <a href="http://www.ahrq.gov/downloads/pub/evidence/pdf/fuiad/fuiad.pdf" class="external free" title="http://www.ahrq.gov/downloads/pub/evidence/pdf/fuiad/fuiad.pdf" rel="nofollow">http://www.ahrq.gov/downloads/pub/evidence/pdf/fuiad/fuiad.pdf</a></li>
<li id="cite_note-2615a-23"><b><a href="#cite_ref-2615a_23-0" title="">^</a></b> <cite style="font-style:normal" class="web"><a href="http://www.clinicalstudyresults.org/drugdetails/viewfile.php?study_name=Trial+2615a++Efficacy+and+Safety+of+Duloxetine+compared+with+Placebo%2C+Pelvic+Floor+Muscle+Training%2C+and+Combined+Duloxetine%2FPelvic+Floor+Muscle+Training+in+Subjects+with+Moderate+to+Severe+Stress+Urinary+Incontinence&amp;file=http%3A%2F%2Fpdf.clinicalstudyresults.org%2Fdocuments%2Fcompany-study_4001_0.pdf" class="external text" title="http://www.clinicalstudyresults.org/drugdetails/viewfile.php?study_name=Trial+2615a++Efficacy+and+Safety+of+Duloxetine+compared+with+Placebo%2C+Pelvic+Floor+Muscle+Training%2C+and+Combined+Duloxetine%2FPelvic+Floor+Muscle+Training+in+Subjects+with+Moderate+to+Severe+Stress+Urinary+Incontinence&amp;file=http%3A%2F%2Fpdf.clinicalstudyresults.org%2Fdocuments%2Fcompany-study_4001_0.pdf" rel="nofollow">"Trial 2615a Efficacy and Safety of Duloxetine compared with Placebo, Pelvic Floor Muscle Training, and Combined Duloxetine/Pelvic Floor Muscle Training in Subjects with Moderate to Severe Stress Urinary Incontinence"</a> (PDF). www.clinicalstudyresults.org<span class="printonly">. <a href="http://www.clinicalstudyresults.org/drugdetails/viewfile.php?study_name=Trial+2615a++Efficacy+and+Safety+of+Duloxetine+compared+with+Placebo%2C+Pelvic+Floor+Muscle+Training%2C+and+Combined+Duloxetine%2FPelvic+Floor+Muscle+Training+in+Subjects+with+Moderate+to+Severe+Stress+Urinary+Incontinence&amp;file=http%3A%2F%2Fpdf.clinicalstudyresults.org%2Fdocuments%2Fcompany-study_4001_0.pdf" class="external free" title="http://www.clinicalstudyresults.org/drugdetails/viewfile.php?study_name=Trial+2615a++Efficacy+and+Safety+of+Duloxetine+compared+with+Placebo%2C+Pelvic+Floor+Muscle+Training%2C+and+Combined+Duloxetine%2FPelvic+Floor+Muscle+Training+in+Subjects+with+Moderate+to+Severe+Stress+Urinary+Incontinence&amp;file=http%3A%2F%2Fpdf.clinicalstudyresults.org%2Fdocuments%2Fcompany-study_4001_0.pdf" rel="nofollow">http://www.clinicalstudyresults.org/drugdetails/viewfile.php?study_name=Trial+2615a++Efficacy+and+Safety+of+Duloxetine+compared+with+Placebo%2C+Pelvic+Floor+Muscle+Training%2C+and+Combined+Duloxetine%2FPelvic+Floor+Muscle+Training+in+Subjects+with+Moderate+to+Severe+Stress+Urinary+Incontinence&amp;file=http%3A%2F%2Fpdf.clinicalstudyresults.org%2Fdocuments%2Fcompany-study_4001_0.pdf</a></span><span class="reference-accessdate">. Retrieved on 02-03-09</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Trial+2615a+Efficacy+and+Safety+of+Duloxetine+compared+with+Placebo%2C+Pelvic+Floor+Muscle+Training%2C+and+Combined+Duloxetine%2FPelvic+Floor+Muscle+Training+in+Subjects+with+Moderate+to+Severe+Stress+Urinary+Incontinence&amp;rft.atitle=&amp;rft.pub=www.clinicalstudyresults.org&amp;rft_id=http%3A%2F%2Fwww.clinicalstudyresults.org%2Fdrugdetails%2Fviewfile.php%3Fstudy_name%3DTrial%2B2615a%2B%2BEfficacy%2Band%2BSafety%2Bof%2BDuloxetine%2Bcompared%2Bwith%2BPlacebo%252C%2BPelvic%2BFloor%2BMuscle%2BTraining%252C%2Band%2BCombined%2BDuloxetine%252FPelvic%2BFloor%2BMuscle%2BTraining%2Bin%2BSubjects%2Bwith%2BModerate%2Bto%2BSevere%2BStress%2BUrinary%2BIncontinence%26file%3Dhttp%253A%252F%252Fpdf.clinicalstudyresults.org%252Fdocuments%252Fcompany-study_4001_0.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-2615b-24"><b><a href="#cite_ref-2615b_24-0" title="">^</a></b> <cite style="font-style:normal" class="web"><a href="http://www.clinicalstudyresults.org/drugdetails/viewfile.php?study_name=Trial+2615b+Efficacy+and+Safety+of+Duloxetine+compared+with+Placebo%2C+Pelvic+Floor+Muscle+Training%2C+and+Combined+Duloxetine%2FPelvic+Floor+Muscle+Training+in+Subjects+with+Moderate+to+Severe+Stress+Urinary+Incontinence&amp;file=http%3A%2F%2Fpdf.clinicalstudyresults.org%2Fdocuments%2Fcompany-study_2356_0.pdf" class="external text" title="http://www.clinicalstudyresults.org/drugdetails/viewfile.php?study_name=Trial+2615b+Efficacy+and+Safety+of+Duloxetine+compared+with+Placebo%2C+Pelvic+Floor+Muscle+Training%2C+and+Combined+Duloxetine%2FPelvic+Floor+Muscle+Training+in+Subjects+with+Moderate+to+Severe+Stress+Urinary+Incontinence&amp;file=http%3A%2F%2Fpdf.clinicalstudyresults.org%2Fdocuments%2Fcompany-study_2356_0.pdf" rel="nofollow">"Trial 2615b. Efficacy and Safety of Duloxetine compared with Placebo, Pelvic Floor Muscle Training, and Combined Duloxetine/Pelvic Floor Muscle Training in Subjects with Moderate to Severe Stress Urinary Incontinence"</a> (PDF). www.clinicalstudyresults.org<span class="printonly">. <a href="http://www.clinicalstudyresults.org/drugdetails/viewfile.php?study_name=Trial+2615b+Efficacy+and+Safety+of+Duloxetine+compared+with+Placebo%2C+Pelvic+Floor+Muscle+Training%2C+and+Combined+Duloxetine%2FPelvic+Floor+Muscle+Training+in+Subjects+with+Moderate+to+Severe+Stress+Urinary+Incontinence&amp;file=http%3A%2F%2Fpdf.clinicalstudyresults.org%2Fdocuments%2Fcompany-study_2356_0.pdf" class="external free" title="http://www.clinicalstudyresults.org/drugdetails/viewfile.php?study_name=Trial+2615b+Efficacy+and+Safety+of+Duloxetine+compared+with+Placebo%2C+Pelvic+Floor+Muscle+Training%2C+and+Combined+Duloxetine%2FPelvic+Floor+Muscle+Training+in+Subjects+with+Moderate+to+Severe+Stress+Urinary+Incontinence&amp;file=http%3A%2F%2Fpdf.clinicalstudyresults.org%2Fdocuments%2Fcompany-study_2356_0.pdf" rel="nofollow">http://www.clinicalstudyresults.org/drugdetails/viewfile.php?study_name=Trial+2615b+Efficacy+and+Safety+of+Duloxetine+compared+with+Placebo%2C+Pelvic+Floor+Muscle+Training%2C+and+Combined+Duloxetine%2FPelvic+Floor+Muscle+Training+in+Subjects+with+Moderate+to+Severe+Stress+Urinary+Incontinence&amp;file=http%3A%2F%2Fpdf.clinicalstudyresults.org%2Fdocuments%2Fcompany-study_2356_0.pdf</a></span><span class="reference-accessdate">. Retrieved on 02-03-09</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Trial+2615b.+Efficacy+and+Safety+of+Duloxetine+compared+with+Placebo%2C+Pelvic+Floor+Muscle+Training%2C+and+Combined+Duloxetine%2FPelvic+Floor+Muscle+Training+in+Subjects+with+Moderate+to+Severe+Stress+Urinary+Incontinence&amp;rft.atitle=&amp;rft.pub=www.clinicalstudyresults.org&amp;rft_id=http%3A%2F%2Fwww.clinicalstudyresults.org%2Fdrugdetails%2Fviewfile.php%3Fstudy_name%3DTrial%2B2615b%2BEfficacy%2Band%2BSafety%2Bof%2BDuloxetine%2Bcompared%2Bwith%2BPlacebo%252C%2BPelvic%2BFloor%2BMuscle%2BTraining%252C%2Band%2BCombined%2BDuloxetine%252FPelvic%2BFloor%2BMuscle%2BTraining%2Bin%2BSubjects%2Bwith%2BModerate%2Bto%2BSevere%2BStress%2BUrinary%2BIncontinence%26file%3Dhttp%253A%252F%252Fpdf.clinicalstudyresults.org%252Fdocuments%252Fcompany-study_2356_0.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-25"><b><a href="#cite_ref-25" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFGoldstein_DJ.2C_Lu_Y.2C_Detke_MJ.2C_Lee_TC.2C_Iyengar_S2005">Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S (July 2005). "Duloxetine vs. placebo in patients with painful diabetic neuropathy". <i>Pain</i> <b>116</b> (1-2): 109–18. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2Fj.pain.2005.03.029" class="external text" title="http://dx.doi.org/10.1016%2Fj.pain.2005.03.029" rel="nofollow">10.1016/j.pain.2005.03.029</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15927394" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15927394">PMID 15927394</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Duloxetine+vs.+placebo+in+patients+with+painful+diabetic+neuropathy&amp;rft.jtitle=Pain&amp;rft.aulast=Goldstein+DJ%2C+Lu+Y%2C+Detke+MJ%2C+Lee+TC%2C+Iyengar+S&amp;rft.au=Goldstein+DJ%2C+Lu+Y%2C+Detke+MJ%2C+Lee+TC%2C+Iyengar+S&amp;rft.date=July+2005&amp;rft.volume=116&amp;rft.issue=1-2&amp;rft.pages=109%E2%80%9318&amp;rft_id=info:doi/10.1016%2Fj.pain.2005.03.029&amp;rft_id=info:pmid/15927394&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-26"><b><a href="#cite_ref-26" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFRaskin_J.2C_Pritchett_YL.2C_Wang_F.2C_.27.27et_al.27.272005">Raskin J, Pritchett YL, Wang F, <i>et al</i> (2005). "A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain". <i>Pain Med</i> <b>6</b> (5): 346–56. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1111%2Fj.1526-4637.2005.00061.x" class="external text" title="http://dx.doi.org/10.1111%2Fj.1526-4637.2005.00061.x" rel="nofollow">10.1111/j.1526-4637.2005.00061.x</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16266355" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16266355">PMID 16266355</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=A+double-blind%2C+randomized+multicenter+trial+comparing+duloxetine+with+placebo+in+the+management+of+diabetic+peripheral+neuropathic+pain&amp;rft.jtitle=Pain+Med&amp;rft.aulast=Raskin+J%2C+Pritchett+YL%2C+Wang+F%2C+%27%27et+al%27%27&amp;rft.au=Raskin+J%2C+Pritchett+YL%2C+Wang+F%2C+%27%27et+al%27%27&amp;rft.date=2005&amp;rft.volume=6&amp;rft.issue=5&amp;rft.pages=346%E2%80%9356&amp;rft_id=info:doi/10.1111%2Fj.1526-4637.2005.00061.x&amp;rft_id=info:pmid/16266355&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-27"><b><a href="#cite_ref-27" title="">^</a></b> <a href="http://www.esi-topics.com/fbp/2006/june06-MichaelJDetke.html" class="external text" title="http://www.esi-topics.com/fbp/2006/june06-MichaelJDetke.html" rel="nofollow">Essential Science Indicators</a></li>
<li id="cite_note-28"><b><a href="#cite_ref-28" title="">^</a></b> <a href="http://www.news-medical.net/?id=22194" class="external autonumber" title="http://www.news-medical.net/?id=22194" rel="nofollow">[1]</a> News-Medical.Net February 26, 2007</li>
<li id="cite_note-29"><b><a href="#cite_ref-29" title="">^</a></b> <a href="http://www.fmaware.org/fminfo/brochure.htm" class="external autonumber" title="http://www.fmaware.org/fminfo/brochure.htm" rel="nofollow">[2]</a> National Fibromyalgia Association Brochure</li>
<li id="cite_note-Arnold2004-30">^ <a href="#cite_ref-Arnold2004_30-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Arnold2004_30-1" title=""><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Arnold2004_30-2" title=""><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Arnold2004_30-3" title=""><sup><i><b>d</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFArnold_LM.2C_Lu_Y.2C_Crofford_LJ.2C_.27.27et_al.27.272004">Arnold LM, Lu Y, Crofford LJ, <i>et al</i> (September 2004). "<a href="http://www3.interscience.wiley.com/cgi-bin/fulltext/109609649/HTMLSTART" class="external text" title="http://www3.interscience.wiley.com/cgi-bin/fulltext/109609649/HTMLSTART" rel="nofollow">A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder</a>". <i>Arthritis Rheum.</i> <b>50</b> (9): 2974–84. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1002%2Fart.20485" class="external text" title="http://dx.doi.org/10.1002%2Fart.20485" rel="nofollow">10.1002/art.20485</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15457467" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15457467">PMID 15457467</a><span class="printonly">. <a href="http://www3.interscience.wiley.com/cgi-bin/fulltext/109609649/HTMLSTART" class="external free" title="http://www3.interscience.wiley.com/cgi-bin/fulltext/109609649/HTMLSTART" rel="nofollow">http://www3.interscience.wiley.com/cgi-bin/fulltext/109609649/HTMLSTART</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=A+double-blind%2C+multicenter+trial+comparing+duloxetine+with+placebo+in+the+treatment+of+fibromyalgia+patients+with+or+without+major+depressive+disorder&amp;rft.jtitle=Arthritis+Rheum.&amp;rft.aulast=Arnold+LM%2C+Lu+Y%2C+Crofford+LJ%2C+%27%27et+al%27%27&amp;rft.au=Arnold+LM%2C+Lu+Y%2C+Crofford+LJ%2C+%27%27et+al%27%27&amp;rft.date=September+2004&amp;rft.volume=50&amp;rft.issue=9&amp;rft.pages=2974%E2%80%9384&amp;rft_id=info:doi/10.1002%2Fart.20485&amp;rft_id=info:pmid/15457467&amp;rft_id=http%3A%2F%2Fwww3.interscience.wiley.com%2Fcgi-bin%2Ffulltext%2F109609649%2FHTMLSTART&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-31"><b><a href="#cite_ref-31" title="">^</a></b> <cite style="font-style:normal" class="web"><a href="http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=316740" class="external text" title="http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=316740" rel="nofollow">"FDA Approves Cymbalta for the Management of Fibromyalgia"</a>. <i>Eli Lilly Co.</i>. 2008-06-16<span class="printonly">. <a href="http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=316740" class="external free" title="http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=316740" rel="nofollow">http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=316740</a></span><span class="reference-accessdate">. Retrieved on 2008-06-17</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=FDA+Approves+Cymbalta+for+the+Management+of+Fibromyalgia&amp;rft.atitle=Eli+Lilly+Co.&amp;rft.date=2008-06-16&amp;rft_id=http%3A%2F%2Fnewsroom.lilly.com%2FReleaseDetail.cfm%3FReleaseID%3D316740&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-32"><b><a href="#cite_ref-32" title="">^</a></b> <a href="http://clinicaltrials.gov/ct/show/NCT00375973?order=1" class="external autonumber" title="http://clinicaltrials.gov/ct/show/NCT00375973?order=1" rel="nofollow">[3]</a> Clinicaltrials.gov</li>
<li id="cite_note-33"><b><a href="#cite_ref-33" title="">^</a></b> Cymbalta package insert. Indianapolis, IN: Eli Lilly Pharmaceuticals; 2004, September.</li>
<li id="cite_note-34"><b><a href="#cite_ref-34" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFPerahia_DG.2C_Kajdasz_DK.2C_Walker_DJ.2C_Raskin_J.2C_Tylee_A2006">Perahia DG, Kajdasz DK, Walker DJ, Raskin J, Tylee A (May 2006). "<a href="http://www.blackwell-synergy.com/doi/full/10.1111/j.1368-5031.2006.00956.x?cookieSet=1" class="external text" title="http://www.blackwell-synergy.com/doi/full/10.1111/j.1368-5031.2006.00956.x?cookieSet=1" rel="nofollow">Duloxetine 60 mg once daily in the treatment of milder major depressive disorder</a>". <i>Int. J. Clin. Pract.</i> <b>60</b> (5): 613–20. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1111%2Fj.1368-5031.2006.00956.x" class="external text" title="http://dx.doi.org/10.1111%2Fj.1368-5031.2006.00956.x" rel="nofollow">10.1111/j.1368-5031.2006.00956.x</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16700869" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16700869">PMID 16700869</a><span class="printonly">. <a href="http://www.blackwell-synergy.com/doi/full/10.1111/j.1368-5031.2006.00956.x?cookieSet=1" class="external free" title="http://www.blackwell-synergy.com/doi/full/10.1111/j.1368-5031.2006.00956.x?cookieSet=1" rel="nofollow">http://www.blackwell-synergy.com/doi/full/10.1111/j.1368-5031.2006.00956.x?cookieSet=1</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Duloxetine+60+mg+once+daily+in+the+treatment+of+milder+major+depressive+disorder&amp;rft.jtitle=Int.+J.+Clin.+Pract.&amp;rft.aulast=Perahia+DG%2C+Kajdasz+DK%2C+Walker+DJ%2C+Raskin+J%2C+Tylee+A&amp;rft.au=Perahia+DG%2C+Kajdasz+DK%2C+Walker+DJ%2C+Raskin+J%2C+Tylee+A&amp;rft.date=May+2006&amp;rft.volume=60&amp;rft.issue=5&amp;rft.pages=613%E2%80%9320&amp;rft_id=info:doi/10.1111%2Fj.1368-5031.2006.00956.x&amp;rft_id=info:pmid/16700869&amp;rft_id=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Ffull%2F10.1111%2Fj.1368-5031.2006.00956.x%3FcookieSet%3D1&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span> Full text at <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>: <a href="http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=1473178" class="external text" title="http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=1473178" rel="nofollow">1473178</a></li>
<li id="cite_note-35"><b><a href="#cite_ref-35" title="">^</a></b> <a href="http://www.rxlist.com/cgi/generic/cymbalta_ad.htm" class="external autonumber" title="http://www.rxlist.com/cgi/generic/cymbalta_ad.htm" rel="nofollow">[4]</a> Cymbalta Side Effects, and Drug Interactions - RxList Monographs</li>
<li id="cite_note-36"><b><a href="#cite_ref-36" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFAnderson_D.2C_Reed_S.2C_Lintemoot_J.2C_.27.27et_al.27.272006">Anderson D, Reed S, Lintemoot J, <i>et al</i> (October 2006). "A first look at duloxetine (Cymbalta) in a postmortem laboratory". <i>J Anal Toxicol</i> <b>30</b> (8): 576–80. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17132255" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17132255">PMID 17132255</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=A+first+look+at+duloxetine+%28Cymbalta%29+in+a+postmortem+laboratory&amp;rft.jtitle=J+Anal+Toxicol&amp;rft.aulast=Anderson+D%2C+Reed+S%2C+Lintemoot+J%2C+%27%27et+al%27%27&amp;rft.au=Anderson+D%2C+Reed+S%2C+Lintemoot+J%2C+%27%27et+al%27%27&amp;rft.date=October+2006&amp;rft.volume=30&amp;rft.issue=8&amp;rft.pages=576%E2%80%9380&amp;rft_id=info:pmid/17132255&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-37"><b><a href="#cite_ref-37" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFSafdieh_JE.2C_Rudominer_R2006">Safdieh JE, Rudominer R (December 2006). "A case of hyponatremia induced by duloxetine". <i>J Clin Psychopharmacol</i> <b>26</b> (6): 675–6. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1097%2F01.jcp.0000246207.73034.96" class="external text" title="http://dx.doi.org/10.1097%2F01.jcp.0000246207.73034.96" rel="nofollow">10.1097/01.jcp.0000246207.73034.96</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17110834" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17110834">PMID 17110834</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=A+case+of+hyponatremia+induced+by+duloxetine&amp;rft.jtitle=J+Clin+Psychopharmacol&amp;rft.aulast=Safdieh+JE%2C+Rudominer+R&amp;rft.au=Safdieh+JE%2C+Rudominer+R&amp;rft.date=December+2006&amp;rft.volume=26&amp;rft.issue=6&amp;rft.pages=675%E2%80%936&amp;rft_id=info:doi/10.1097%2F01.jcp.0000246207.73034.96&amp;rft_id=info:pmid/17110834&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-38"><b><a href="#cite_ref-38" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFDeuschle_M.2C_Mase_E.2C_Zink_M2006">Deuschle M, Mase E, Zink M (November 2006). "Dyskinesia during treatment with duloxetine". <i>Pharmacopsychiatry</i> <b>39</b> (6): 237–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1055%2Fs-2006-951608" class="external text" title="http://dx.doi.org/10.1055%2Fs-2006-951608" rel="nofollow">10.1055/s-2006-951608</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17124651" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17124651">PMID 17124651</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Dyskinesia+during+treatment+with+duloxetine&amp;rft.jtitle=Pharmacopsychiatry&amp;rft.aulast=Deuschle+M%2C+Mase+E%2C+Zink+M&amp;rft.au=Deuschle+M%2C+Mase+E%2C+Zink+M&amp;rft.date=November+2006&amp;rft.volume=39&amp;rft.issue=6&amp;rft.pages=237%E2%80%938&amp;rft_id=info:doi/10.1055%2Fs-2006-951608&amp;rft_id=info:pmid/17124651&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-39"><b><a href="#cite_ref-39" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFStrouse_TB.2C_Kerrihard_TN.2C_Forscher_CA.2C_Zakowski_P2006">Strouse TB, Kerrihard TN, Forscher CA, Zakowski P (December 2006). "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine". <i>J Clin Psychopharmacol</i> <b>26</b> (6): 681–3. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1097%2F01.jcp.0000239793.29449.75" class="external text" title="http://dx.doi.org/10.1097%2F01.jcp.0000239793.29449.75" rel="nofollow">10.1097/01.jcp.0000239793.29449.75</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17110838" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17110838">PMID 17110838</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Serotonin+syndrome+precipitated+by+linezolid+in+a+medically+ill+patient+on+duloxetine&amp;rft.jtitle=J+Clin+Psychopharmacol&amp;rft.aulast=Strouse+TB%2C+Kerrihard+TN%2C+Forscher+CA%2C+Zakowski+P&amp;rft.au=Strouse+TB%2C+Kerrihard+TN%2C+Forscher+CA%2C+Zakowski+P&amp;rft.date=December+2006&amp;rft.volume=26&amp;rft.issue=6&amp;rft.pages=681%E2%80%933&amp;rft_id=info:doi/10.1097%2F01.jcp.0000239793.29449.75&amp;rft_id=info:pmid/17110838&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-40"><b><a href="#cite_ref-40" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFKeegan_MT.2C_Brown_DR.2C_Rabinstein_AA2006">Keegan MT, Brown DR, Rabinstein AA (December 2006). "<a href="http://www.anesthesia-analgesia.org/cgi/content/full/103/6/1466" class="external text" title="http://www.anesthesia-analgesia.org/cgi/content/full/103/6/1466" rel="nofollow">Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs</a>". <i>Anesth. Analg.</i> <b>103</b> (6): 1466–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1213%2F01.ane.0000247699.81580.eb" class="external text" title="http://dx.doi.org/10.1213%2F01.ane.0000247699.81580.eb" rel="nofollow">10.1213/01.ane.0000247699.81580.eb</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17122225" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17122225">PMID 17122225</a><span class="printonly">. <a href="http://www.anesthesia-analgesia.org/cgi/content/full/103/6/1466" class="external free" title="http://www.anesthesia-analgesia.org/cgi/content/full/103/6/1466" rel="nofollow">http://www.anesthesia-analgesia.org/cgi/content/full/103/6/1466</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Serotonin+syndrome+from+the+interaction+of+cyclobenzaprine+with+other+serotoninergic+drugs&amp;rft.jtitle=Anesth.+Analg.&amp;rft.aulast=Keegan+MT%2C+Brown+DR%2C+Rabinstein+AA&amp;rft.au=Keegan+MT%2C+Brown+DR%2C+Rabinstein+AA&amp;rft.date=December+2006&amp;rft.volume=103&amp;rft.issue=6&amp;rft.pages=1466%E2%80%938&amp;rft_id=info:doi/10.1213%2F01.ane.0000247699.81580.eb&amp;rft_id=info:pmid/17122225&amp;rft_id=http%3A%2F%2Fwww.anesthesia-analgesia.org%2Fcgi%2Fcontent%2Ffull%2F103%2F6%2F1466&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-41"><b><a href="#cite_ref-41" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFHanje_AJ.2C_Pell_LJ.2C_Votolato_NA.2C_Frankel_WL.2C_Kirkpatrick_RB2006">Hanje AJ, Pell LJ, Votolato NA, Frankel WL, Kirkpatrick RB (July 2006). "Case report: fulminant hepatic failure involving duloxetine hydrochloride". <i>Clin. Gastroenterol. Hepatol.</i> <b>4</b> (7): 912–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2Fj.cgh.2006.04.018" class="external text" title="http://dx.doi.org/10.1016%2Fj.cgh.2006.04.018" rel="nofollow">10.1016/j.cgh.2006.04.018</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16797245" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16797245">PMID 16797245</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Case+report%3A+fulminant+hepatic+failure+involving+duloxetine+hydrochloride&amp;rft.jtitle=Clin.+Gastroenterol.+Hepatol.&amp;rft.aulast=Hanje+AJ%2C+Pell+LJ%2C+Votolato+NA%2C+Frankel+WL%2C+Kirkpatrick+RB&amp;rft.au=Hanje+AJ%2C+Pell+LJ%2C+Votolato+NA%2C+Frankel+WL%2C+Kirkpatrick+RB&amp;rft.date=July+2006&amp;rft.volume=4&amp;rft.issue=7&amp;rft.pages=912%E2%80%937&amp;rft_id=info:doi/10.1016%2Fj.cgh.2006.04.018&amp;rft_id=info:pmid/16797245&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-42"><b><a href="#cite_ref-42" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFLoper_T.2C_Touchet_B2007">Loper T, Touchet B (2007). "<a href="http://psy.psychiatryonline.org/cgi/content/full/48/2/179" class="external text" title="http://psy.psychiatryonline.org/cgi/content/full/48/2/179" rel="nofollow">An acute attack of porphyria in a patient taking duloxetine</a>". <i>Psychosomatics</i> <b>48</b> (2): 179–80. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1176%2Fappi.psy.48.2.179" class="external text" title="http://dx.doi.org/10.1176%2Fappi.psy.48.2.179" rel="nofollow">10.1176/appi.psy.48.2.179</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17329617" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17329617">PMID 17329617</a><span class="printonly">. <a href="http://psy.psychiatryonline.org/cgi/content/full/48/2/179" class="external free" title="http://psy.psychiatryonline.org/cgi/content/full/48/2/179" rel="nofollow">http://psy.psychiatryonline.org/cgi/content/full/48/2/179</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=An+acute+attack+of+porphyria+in+a+patient+taking+duloxetine&amp;rft.jtitle=Psychosomatics&amp;rft.aulast=Loper+T%2C+Touchet+B&amp;rft.au=Loper+T%2C+Touchet+B&amp;rft.date=2007&amp;rft.volume=48&amp;rft.issue=2&amp;rft.pages=179%E2%80%9380&amp;rft_id=info:doi/10.1176%2Fappi.psy.48.2.179&amp;rft_id=info:pmid/17329617&amp;rft_id=http%3A%2F%2Fpsy.psychiatryonline.org%2Fcgi%2Fcontent%2Ffull%2F48%2F2%2F179&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-43"><b><a href="#cite_ref-43" title="">^</a></b> Cymbalta patient information sheet. Indianapolis, IN: Eli Lilly Pharmaceuticals; July 2006</li>
<li id="cite_note-44"><b><a href="#cite_ref-44" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFPerahia_DG.2C_Kajdasz_DK.2C_Desaiah_D.2C_Haddad_PM2005">Perahia DG, Kajdasz DK, Desaiah D, Haddad PM (December 2005). "Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder". <i>J Affect Disord</i> <b>89</b> (1-3): 207–12. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2Fj.jad.2005.09.003" class="external text" title="http://dx.doi.org/10.1016%2Fj.jad.2005.09.003" rel="nofollow">10.1016/j.jad.2005.09.003</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16266753" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16266753">PMID 16266753</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Symptoms+following+abrupt+discontinuation+of+duloxetine+treatment+in+patients+with+major+depressive+disorder&amp;rft.jtitle=J+Affect+Disord&amp;rft.aulast=Perahia+DG%2C+Kajdasz+DK%2C+Desaiah+D%2C+Haddad+PM&amp;rft.au=Perahia+DG%2C+Kajdasz+DK%2C+Desaiah+D%2C+Haddad+PM&amp;rft.date=December+2005&amp;rft.volume=89&amp;rft.issue=1-3&amp;rft.pages=207%E2%80%9312&amp;rft_id=info:doi/10.1016%2Fj.jad.2005.09.003&amp;rft_id=info:pmid/16266753&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-FDA-45"><b><a href="#cite_ref-FDA_45-0" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREFLevenson_M.2C_Holland_C">Levenson M, Holland C. <a href="http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4272s1-04-FDA.ppt" class="external text" title="http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4272s1-04-FDA.ppt" rel="nofollow">"Antidepressants and Suicidality in Adults: Statistical Evaluation. (Presentation at Psychopharmacologic Drugs Advisory Committee; December 13, 2006)"</a><span class="printonly">. <a href="http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4272s1-04-FDA.ppt" class="external free" title="http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4272s1-04-FDA.ppt" rel="nofollow">http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4272s1-04-FDA.ppt</a></span><span class="reference-accessdate">. Retrieved on 2007-05-13</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Antidepressants+and+Suicidality+in+Adults%3A+Statistical+Evaluation.+%28Presentation+at+Psychopharmacologic+Drugs+Advisory+Committee%3B+December+13%2C+2006%29&amp;rft.atitle=&amp;rft.aulast=Levenson+M%2C+Holland+C&amp;rft.au=Levenson+M%2C+Holland+C&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2Fohrms%2Fdockets%2Fac%2F06%2Fslides%2F2006-4272s1-04-FDA.ppt&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-FDA2-46">^ <a href="#cite_ref-FDA2_46-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA2_46-1" title=""><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA2_46-2" title=""><sup><i><b>c</b></i></sup></a> <cite style="font-style:normal" class="web" id="CITEREFStone_MB.2C_Jones_ML2006">Stone MB, Jones ML (2006-11-17). <a href="http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf" class="external text" title="http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf" rel="nofollow">"CLINICAL REVIEW: RELATIONSHIP BETWEEN ANTIDEPRESSANT DRUGS AND SUICIDALITY IN ADULTS"</a> (PDF). <i>Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC)</i>. FDA. 11–74<span class="printonly">. <a href="http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf" class="external free" title="http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf" rel="nofollow">http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf</a></span><span class="reference-accessdate">. Retrieved on 2007-09-22</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=CLINICAL+REVIEW%3A+RELATIONSHIP+BETWEEN+ANTIDEPRESSANT+DRUGS+AND+SUICIDALITY+IN+ADULTS&amp;rft.atitle=Overview+for+December+13+Meeting+of+Psychopharmacologic+Drugs+Advisory+Committee+%28PDAC%29&amp;rft.aulast=Stone+MB%2C+Jones+ML&amp;rft.au=Stone+MB%2C+Jones+ML&amp;rft.date=2006-11-17&amp;rft.pages=11%E2%80%9374&amp;rft.pub=FDA&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2Fohrms%2Fdockets%2Fac%2F06%2Fbriefing%2F2006-4272b1-01-FDA.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-FDA3-47">^ <a href="#cite_ref-FDA3_47-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA3_47-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="web" id="CITEREFLevenson_M.2C_Holland_C2006">Levenson M, Holland C (2006-11-17). <a href="http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf" class="external text" title="http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf" rel="nofollow">"Statistical Evaluation of Suicidality in Adults Treated with Antidepressants"</a> (PDF). <i>Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC)</i>. FDA. 75–140<span class="printonly">. <a href="http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf" class="external free" title="http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf" rel="nofollow">http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf</a></span><span class="reference-accessdate">. Retrieved on 2007-09-22</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Statistical+Evaluation+of+Suicidality+in+Adults+Treated+with+Antidepressants&amp;rft.atitle=Overview+for+December+13+Meeting+of+Psychopharmacologic+Drugs+Advisory+Committee+%28PDAC%29&amp;rft.aulast=Levenson+M%2C+Holland+C&amp;rft.au=Levenson+M%2C+Holland+C&amp;rft.date=2006-11-17&amp;rft.pages=75%E2%80%93140&amp;rft.pub=FDA&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2Fohrms%2Fdockets%2Fac%2F06%2Fbriefing%2F2006-4272b1-01-FDA.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid17453659-48"><b><a href="#cite_ref-pmid17453659_48-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFKhan_A.2C_Schwartz_K2007">Khan A, Schwartz K (2007). "Suicide risk and symptom reduction in patients assigned to placebo in duloxetine and escitalopram clinical trials: analysis of the FDA summary basis of approval reports". <i>Ann Clin Psychiatry</i> <b>19</b> (1): 31–6. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1080%2F10401230601163550" class="external text" title="http://dx.doi.org/10.1080%2F10401230601163550" rel="nofollow">10.1080/10401230601163550</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17453659" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17453659">PMID 17453659</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Suicide+risk+and+symptom+reduction+in+patients+assigned+to+placebo+in+duloxetine+and+escitalopram+clinical+trials%3A+analysis+of+the+FDA+summary+basis+of+approval+reports&amp;rft.jtitle=Ann+Clin+Psychiatry&amp;rft.aulast=Khan+A%2C+Schwartz+K&amp;rft.au=Khan+A%2C+Schwartz+K&amp;rft.date=2007&amp;rft.volume=19&amp;rft.issue=1&amp;rft.pages=31%E2%80%936&amp;rft_id=info:doi/10.1080%2F10401230601163550&amp;rft_id=info:pmid/17453659&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Slate-49"><b><a href="#cite_ref-Slate_49-0" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREFJeanne_Lenzer2005">Jeanne Lenzer (2005-09-27). <a href="http://www.slate.com/id/2126918/" class="external text" title="http://www.slate.com/id/2126918/" rel="nofollow">"What the FDA isn't telling."</a> (html). Slate Magazine<span class="printonly">. <a href="http://www.slate.com/id/2126918/" class="external free" title="http://www.slate.com/id/2126918/" rel="nofollow">http://www.slate.com/id/2126918/</a></span><span class="reference-accessdate">. Retrieved on 2008-01-20</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=What+the+FDA+isn%27t+telling.&amp;rft.atitle=&amp;rft.aulast=Jeanne+Lenzer&amp;rft.au=Jeanne+Lenzer&amp;rft.date=2005-09-27&amp;rft.pub=Slate+Magazine&amp;rft_id=http%3A%2F%2Fwww.slate.com%2Fid%2F2126918%2F&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-independent-50">^ <a href="#cite_ref-independent_50-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-independent_50-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="web" id="CITEREFJeanne_Lenzer_and_Nicholas_Pyke2005">Jeanne Lenzer and Nicholas Pyke (2005-06-05). <a href="http://news.independent.co.uk/health/article226432.ece" class="external text" title="http://news.independent.co.uk/health/article226432.ece" rel="nofollow">"Was Traci Johnson driven to suicide by anti-depressants? That's a trade secret, say US officials"</a> (html). Independent Online Edition<span class="printonly">. <a href="http://news.independent.co.uk/health/article226432.ece" class="external free" title="http://news.independent.co.uk/health/article226432.ece" rel="nofollow">http://news.independent.co.uk/health/article226432.ece</a></span><span class="reference-accessdate">. Retrieved on 2008-01-20</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Was+Traci+Johnson+driven+to+suicide+by+anti-depressants%3F+That%27s+a+trade+secret%2C+say+US+officials&amp;rft.atitle=&amp;rft.aulast=Jeanne+Lenzer+and+Nicholas+Pyke&amp;rft.au=Jeanne+Lenzer+and+Nicholas+Pyke&amp;rft.date=2005-06-05&amp;rft.pub=Independent+Online+Edition&amp;rft_id=http%3A%2F%2Fnews.independent.co.uk%2Fhealth%2Farticle226432.ece&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-51"><b><a href="#cite_ref-51" title="">^</a></b> <cite style="font-style:normal" class="web"><a href="http://www.fda.gov/cder/drug/infopage/duloxetine/historical.htm" class="external text" title="http://www.fda.gov/cder/drug/infopage/duloxetine/historical.htm" rel="nofollow">"Historical Information on Duloxetine hydrochloride (marketed as Cymbalta)"</a> (html). FDA. 2005-06<span class="printonly">. <a href="http://www.fda.gov/cder/drug/infopage/duloxetine/historical.htm" class="external free" title="http://www.fda.gov/cder/drug/infopage/duloxetine/historical.htm" rel="nofollow">http://www.fda.gov/cder/drug/infopage/duloxetine/historical.htm</a></span><span class="reference-accessdate">. Retrieved on 2008-01-20</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Historical+Information+on+Duloxetine+hydrochloride+%28marketed+as+Cymbalta%29&amp;rft.atitle=&amp;rft.date=2005-06&amp;rft.pub=FDA&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2Fcder%2Fdrug%2Finfopage%2Fduloxetine%2Fhistorical.htm&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-52"><b><a href="#cite_ref-52" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFParikh_AR.3B_Thatcher_BT.3B_Tamano_EA.3B_Liskow_BI2008">Parikh AR; Thatcher BT; Tamano EA; Liskow BI (2008). "Suicidal Ideation Associated With Duloxetine Use: A Case Series". <i>J Clin Psychopharmacolgy</i> <b>28</b> (1): 102.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Suicidal+Ideation+Associated+With+Duloxetine+Use%3A+A+Case+Series&amp;rft.jtitle=J+Clin+Psychopharmacolgy&amp;rft.aulast=Parikh+AR%3B+Thatcher+BT%3B+Tamano+EA%3B+Liskow+BI&amp;rft.au=Parikh+AR%3B+Thatcher+BT%3B+Tamano+EA%3B+Liskow+BI&amp;rft.date=2008&amp;rft.volume=28&amp;rft.issue=1&amp;rft.pages=102&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-53"><b><a href="#cite_ref-53" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREFWalter_F._Naedele2004">Walter F. Naedele (2004-02-12). <a href="http://www.philly.com/mld/inquirer/news/local/7932602.htm" class="external text" title="http://www.philly.com/mld/inquirer/news/local/7932602.htm" rel="nofollow">"Drug test altered in wake of suicide"</a> (html). Philadelphia Inquirer<span class="printonly">. <a href="http://www.philly.com/mld/inquirer/news/local/7932602.htm" class="external free" title="http://www.philly.com/mld/inquirer/news/local/7932602.htm" rel="nofollow">http://www.philly.com/mld/inquirer/news/local/7932602.htm</a></span><span class="reference-accessdate">. Retrieved on 2008-01-20</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Drug+test+altered+in+wake+of+suicide&amp;rft.atitle=&amp;rft.aulast=Walter+F.+Naedele&amp;rft.au=Walter+F.+Naedele&amp;rft.date=2004-02-12&amp;rft.pub=Philadelphia+Inquirer&amp;rft_id=http%3A%2F%2Fwww.philly.com%2Fmld%2Finquirer%2Fnews%2Flocal%2F7932602.htm&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-NYT-54">^ <a href="#cite_ref-NYT_54-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NYT_54-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="web" id="CITEREFGardiner_Harris2004">Gardiner Harris (2004-02-12). <a href="http://query.nytimes.com/gst/fullpage.html?res=9C03E5D8133AF931A25751C0A9629C8B63" class="external text" title="http://query.nytimes.com/gst/fullpage.html?res=9C03E5D8133AF931A25751C0A9629C8B63" rel="nofollow">"Student, 19, in Trial of New Antidepressant Commits Suicide"</a> (html). New York Times<span class="printonly">. <a href="http://query.nytimes.com/gst/fullpage.html?res=9C03E5D8133AF931A25751C0A9629C8B63" class="external free" title="http://query.nytimes.com/gst/fullpage.html?res=9C03E5D8133AF931A25751C0A9629C8B63" rel="nofollow">http://query.nytimes.com/gst/fullpage.html?res=9C03E5D8133AF931A25751C0A9629C8B63</a></span><span class="reference-accessdate">. Retrieved on 2008-01-20</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Student%2C+19%2C+in+Trial+of+New+Antidepressant+Commits+Suicide&amp;rft.atitle=&amp;rft.aulast=Gardiner+Harris&amp;rft.au=Gardiner+Harris&amp;rft.date=2004-02-12&amp;rft.pub=New+York+Times&amp;rft_id=http%3A%2F%2Fquery.nytimes.com%2Fgst%2Ffullpage.html%3Fres%3D9C03E5D8133AF931A25751C0A9629C8B63&amp;rfr_id=info:sid/en.wikipedia.org:Duloxetine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-55"><b><a href="#cite_ref-55" title="">^</a></b> Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT. "Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human <a href="/wiki/5-HT_receptor" title="5-HT receptor">serotonin receptor</a> subtypes, and other neuronal receptors". Neuropsychopharmacology. 2001 Dec;25(6):871-80</li>
</ol>
</div>
<p><a name="External_links" id="External_links"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Duloxetine&amp;action=edit&amp;section=17" title="Edit section: External links">edit</a>]</span> <span class="mw-headline">External links</span></h2>
<ul>
<li><a href="http://www.cymbalta.com/" class="external text" title="http://www.cymbalta.com/" rel="nofollow">Manufacturer website</a></li>
<li><a href="http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/500549.html" class="external text" title="http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/500549.html" rel="nofollow">Duloxetine</a> - medlineplus.org</li>
<li><a href="http://pi.lilly.com/us/cymbalta-pi.pdf" class="external text" title="http://pi.lilly.com/us/cymbalta-pi.pdf" rel="nofollow">Eli Lilly Cymbalta Prescribing Guide</a></li>
<li><a href="http://www.fda.gov/cder/drug/InfoSheets/HCP/duloxetineHCP.htm" class="external text" title="http://www.fda.gov/cder/drug/InfoSheets/HCP/duloxetineHCP.htm" rel="nofollow">FDA Alert for Healthcare Professionals - Cymbalta Serotonin Syndrome</a></li>
<li><a href="http://www.fda.gov/cder/drug/infosheets/patient/duloxetinePIS.pdf" class="external text" title="http://www.fda.gov/cder/drug/infosheets/patient/duloxetinePIS.pdf" rel="nofollow">FDA Patient Information Sheet on Cymbalta</a></li>
</ul>
<table class="navbox" cellspacing="0" style=";">
<tr>
<td style="padding:2px;">
<table cellspacing="0" class="nowraplinks collapsible autocollapse" style="width:100%;background:transparent;color:inherit;;">
<tr>
<th style=";" colspan="2" class="navbox-title">
<div style="float:left; width:6em;text-align:left;">
<div class="noprint plainlinksneverexpand navbar" style="background:none; padding:0; font-weight:normal;;;border:none;; font-size:xx-small;"><a href="/wiki/Template:Antidepressants" title="Template:Antidepressants"><span title="View this template" style=";;border:none;">v</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<a href="/wiki/Template_talk:Antidepressants" title="Template talk:Antidepressants"><span title="Discussion about this template" style=";;border:none;">d</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<a href="http://en.wikipedia.org/w/index.php?title=Template:Antidepressants&amp;action=edit" class="external text" title="http://en.wikipedia.org/w/index.php?title=Template:Antidepressants&amp;action=edit" rel="nofollow"><span title="Edit this template" style=";;border:none;;">e</span></a></div>
</div>
<span style="font-size:110%;"><a href="/wiki/Psychoanaleptic" title="Psychoanaleptic">Psychoanaleptics</a>: <a href="/wiki/Antidepressant" title="Antidepressant">antidepressants</a> (<a href="/wiki/ATC_code_N06#N06A_Antidepressants" title="ATC code N06">N06A</a>)</span></th>
</tr>
<tr style="height:2px;">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background: LightYellow;"><a href="/wiki/Monoamine_oxidase_inhibitor" title="Monoamine oxidase inhibitor">MAOIs</a></td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><i>nonselective:</i> <i>non-reversible</i> (<a href="/wiki/Isocarboxazid" title="Isocarboxazid">Isocarboxazid</a>, <a href="/wiki/Iproclozide" title="Iproclozide">Iproclozide</a>, <a href="/wiki/Iproniazid" title="Iproniazid">Iproniazid</a>, <a href="/wiki/Nialamide" title="Nialamide">Nialamide</a>, <a href="/wiki/Phenelzine" title="Phenelzine">Phenelzine</a>, <a href="/wiki/Pheniprazine" title="Pheniprazine">Pheniprazine</a>) • <i>reversible</i> (<a href="/wiki/Tranylcypromine" title="Tranylcypromine">Tranylcypromine</a>)
<p><i><a href="/wiki/Monoamine_oxidase_A" title="Monoamine oxidase A">MAOA</a> (<a href="/wiki/Norepinephrine" title="Norepinephrine">N</a>/<a href="/wiki/Serotonin" title="Serotonin">S</a>):</i> <a href="/wiki/Clorgiline" title="Clorgiline">Clorgiline</a> • <a href="/wiki/Minaprine" title="Minaprine">Minaprine</a> • <i><a href="/wiki/Reversible_inhibitor_of_monoamine_oxidase_A" title="Reversible inhibitor of monoamine oxidase A">RIMAs</a></i> (<a href="/wiki/Befloxatone" title="Befloxatone">Befloxatone</a>, <a href="/wiki/Brofaromine" title="Brofaromine">Brofaromine</a>, <a href="/wiki/Cimoxatone" title="Cimoxatone">Cimoxatone</a>, <a href="/wiki/Harmaline" title="Harmaline">Harmaline</a>, <a href="/wiki/Moclobemide" title="Moclobemide">Moclobemide</a>, <a href="/wiki/Pirlindole" title="Pirlindole">Pirlindole</a>, <a href="/wiki/Toloxatone" title="Toloxatone">Toloxatone</a>)</p>
<i><a href="/wiki/Monoamine_oxidase_B" title="Monoamine oxidase B">MAOB</a> (<a href="/wiki/Dopamine" title="Dopamine">D</a>):</i> <a href="/wiki/Rasagiline" title="Rasagiline">Rasagiline</a> • <a href="/wiki/Selegiline" title="Selegiline">Selegiline</a> • <a href="/wiki/Pargyline" title="Pargyline">Pargyline</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background: LightYellow;"><a href="/wiki/Neurotransmitter_uptake_inhibitor" title="Neurotransmitter uptake inhibitor">RIs</a></td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="width:100%;;;;">
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background: LightYellow;">
<div style="padding:0em 0.75em;"><a href="/wiki/Serotonin_uptake_inhibitor" title="Serotonin uptake inhibitor">S RI</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/Selective_serotonin_reuptake_inhibitor" title="Selective serotonin reuptake inhibitor">SS RI</a> (<a href="/wiki/Alaproclate" title="Alaproclate">Alaproclate</a>, <a href="/wiki/Citalopram" title="Citalopram">Citalopram</a>, <a href="/wiki/Dapoxetine" title="Dapoxetine">Dapoxetine</a>, <a href="/wiki/Escitalopram" title="Escitalopram">Escitalopram</a>, <a href="/wiki/Femoxetine" title="Femoxetine">Femoxetine</a>, <a href="/wiki/Fluoxetine" title="Fluoxetine">Fluoxetine</a>, <a href="/wiki/Fluvoxamine" title="Fluvoxamine">Fluvoxamine</a>, <a href="/wiki/Paroxetine" title="Paroxetine">Paroxetine</a>, <a href="/wiki/Sertraline" title="Sertraline">Sertraline</a>, <a href="/wiki/Vilazodone" title="Vilazodone">Vilazodone</a>, <a href="/wiki/Zimelidine" title="Zimelidine">Zimelidine</a>)<br />
<i><a href="/wiki/Tricyclic_antidepressant" title="Tricyclic antidepressant">TCAs</a>/<a href="/wiki/Tetracyclic_antidepressant" title="Tetracyclic antidepressant">Tetras</a></i> (<a href="/wiki/Cianopramine" title="Cianopramine">Cianopramine</a>, <a href="/wiki/Clomipramine" title="Clomipramine">Clomipramine</a>, <a href="/wiki/Nefazodone" title="Nefazodone">Nefazodone</a>, <a href="/wiki/Trazodone" title="Trazodone">Trazodone</a>)</div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background: LightYellow;">
<div style="padding:0em 0.75em;"><a href="/wiki/Norepinephrine_reuptake_inhibitor" title="Norepinephrine reuptake inhibitor">N RI</a> / <a href="/wiki/Adrenergic_uptake_inhibitor" title="Adrenergic uptake inhibitor">A RI</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><a href="/wiki/Atomoxetine" title="Atomoxetine">Atomoxetine</a> • <a href="/wiki/Ciclazindol" title="Ciclazindol">Ciclazindol</a> • <a href="/wiki/Maprotiline" title="Maprotiline">Maprotiline</a> • <a href="/wiki/Nisoxetine" title="Nisoxetine">Nisoxetine</a> • <a href="/wiki/Oxaprotiline" title="Oxaprotiline">Oxaprotiline</a> • <a href="/wiki/Reboxetine" title="Reboxetine">Reboxetine</a> • <a href="/wiki/Talopram" title="Talopram">Talopram</a> • <a href="/wiki/Viloxazine" title="Viloxazine">Viloxazine</a><br />
<i><a href="/wiki/Tricyclic_antidepressant" title="Tricyclic antidepressant">TCAs</a>/<a href="/wiki/Tetracyclic_antidepressant" title="Tetracyclic antidepressant">Tetras</a></i> (<a href="/wiki/Amoxapine" title="Amoxapine">Amoxapine</a>, <a href="/wiki/Butriptyline" title="Butriptyline">Butriptyline</a>, <a href="/wiki/Desipramine" title="Desipramine">Desipramine</a>/<a href="/wiki/Lofepramine" title="Lofepramine">Lofepramine</a>, <a href="/wiki/Dibenzepin" title="Dibenzepin">Dibenzepin</a>, <a href="/wiki/Dosulepin_hydrochloride" title="Dosulepin hydrochloride">Dosulepin</a>, <a href="/wiki/Doxepin" title="Doxepin">Doxepin</a>, <a href="/wiki/Imipramine" title="Imipramine">Imipramine</a>, <a href="/wiki/Iprindole" title="Iprindole">Iprindole</a>, <a href="/wiki/Melitracen" title="Melitracen">Melitracen</a>, <a href="/wiki/Nitroxazepine" title="Nitroxazepine">Nitroxazepine</a>, <a href="/wiki/Nortriptyline" title="Nortriptyline">Nortriptyline</a>, <a href="/wiki/Protriptyline" title="Protriptyline">Protriptyline</a>, <a href="/wiki/Trimipramine" title="Trimipramine">Trimipramine</a>)</div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background: LightYellow;">
<div style="padding:0em 0.75em;"><a href="/wiki/Dopamine_reuptake_inhibitor" title="Dopamine reuptake inhibitor">D RI</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/Medifoxamine" title="Medifoxamine">Medifoxamine</a> • <a href="/wiki/Vanoxerine" title="Vanoxerine">Vanoxerine</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background: LightYellow;">
<div style="padding:0em 0.75em;"><a href="/wiki/Serotonin-norepinephrine_reuptake_inhibitor" title="Serotonin-norepinephrine reuptake inhibitor">SN RI</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><a href="/wiki/Bicifadine" title="Bicifadine">Bicifadine</a> • <a href="/wiki/Clovoxamine" title="Clovoxamine">Clovoxamine</a> • <a href="/wiki/Desvenlafaxine" title="Desvenlafaxine">Desvenlafaxine</a> • <strong class="selflink">Duloxetine</strong> • <a href="/wiki/Indeloxazine" title="Indeloxazine">Indeloxazine</a> • <a href="/wiki/Milnacipran" title="Milnacipran">Milnacipran</a> • <a href="/wiki/Nefazodone" title="Nefazodone">Nefazodone</a> • <a href="/wiki/Venlafaxine" title="Venlafaxine">Venlafaxine</a><br />
<i><a href="/wiki/Tricyclic_antidepressant" title="Tricyclic antidepressant">TCAs</a></i> (<a href="/wiki/Amitriptyline" title="Amitriptyline">Amitriptyline</a>)</div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background: LightYellow;">
<div style="padding:0em 0.75em;"><a href="/wiki/Norepinephrine-dopamine_reuptake_inhibitor" title="Norepinephrine-dopamine reuptake inhibitor">ND RI</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/Amineptine" title="Amineptine">Amineptine</a> • <a href="/wiki/Bupropion" title="Bupropion">Bupropion</a> • <a href="/wiki/Nomifensine" title="Nomifensine">Nomifensine</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background: LightYellow;">
<div style="padding:0em 0.75em;"><a href="/wiki/Serotonin-noradrenaline-dopamine_reuptake_inhibitor" title="Serotonin-noradrenaline-dopamine reuptake inhibitor">SND RI</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><a href="/wiki/Brasofensine" title="Brasofensine">Brasofensine</a> • <a href="/wiki/Diclofensine" title="Diclofensine">Diclofensine</a> • <a href="/wiki/Tesofensine" title="Tesofensine">Tesofensine</a></div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background: LightYellow;"><a href="/wiki/Selective_serotonin_reuptake_enhancer" title="Selective serotonin reuptake enhancer">SSREs</a></td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><i><a href="/wiki/Tricyclic_antidepressant" title="Tricyclic antidepressant">TCAs</a></i> (<a href="/wiki/Tianeptine" title="Tianeptine">Tianeptine</a>)</div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background: LightYellow;"><a href="/wiki/Adrenergic_antagonist" title="Adrenergic antagonist">AAs</a> at <a href="/wiki/Alpha-2_adrenergic_receptor" title="Alpha-2 adrenergic receptor">A2</a></td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><i><a href="/wiki/Tetracyclic_antidepressant" title="Tetracyclic antidepressant">Tetras</a></i> (<a href="/wiki/Mianserin" title="Mianserin">Mianserin</a>, <a href="/wiki/Mirtazapine" title="Mirtazapine">Mirtazapine</a>)</div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background: LightYellow;"><a href="/wiki/Sigma_receptor#Agonists" title="Sigma receptor">SAs</a></td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><i><a href="/wiki/Tricyclic_antidepressant" title="Tricyclic antidepressant">TCAs</a></i> (<a href="/wiki/Opipramol" title="Opipramol">Opipramol</a>)</div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background: LightYellow;"><a href="/wiki/Melatonin_receptor" title="Melatonin receptor">MAs</a></td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><i><a href="/wiki/Melatonin_receptor#Agonists" title="Melatonin receptor">Melatonin receptor agonists</a></i> (<a href="/wiki/Agomelatine" title="Agomelatine">Agomelatine</a>)</div>
</td>
</tr>
</table>
</td>
</tr>
</table>


<!-- 
NewPP limit report
Preprocessor node count: 24264/1000000
Post-expand include size: 274820/2048000 bytes
Template argument size: 111806/2048000 bytes
Expensive parser function count: 7/500
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:566616-0!1!0!default!!en!2 and timestamp 20090408232844 -->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org/wiki/Duloxetine">http://en.wikipedia.org/wiki/Duloxetine</a>"</div>
			<div id='catlinks' class='catlinks'><div id="mw-normal-catlinks"><a href="/wiki/Special:Categories" title="Special:Categories">Categories</a>:&#32;<span dir='ltr'><a href="/wiki/Category:Serotonin-norepinephrine_reuptake_inhibitors" title="Category:Serotonin-norepinephrine reuptake inhibitors">Serotonin-norepinephrine reuptake inhibitors</a></span> | <span dir='ltr'><a href="/wiki/Category:Eli_Lilly_and_Company" title="Category:Eli Lilly and Company">Eli Lilly and Company</a></span> | <span dir='ltr'><a href="/wiki/Category:Thiophenes" title="Category:Thiophenes">Thiophenes</a></span></div><div id="mw-hidden-catlinks" class="mw-hidden-cats-hidden">Hidden categories:&#32;<span dir='ltr'><a href="/wiki/Category:Medicine_articles_needing_expert_attention" title="Category:Medicine articles needing expert attention">Medicine articles needing expert attention</a></span> | <span dir='ltr'><a href="/wiki/Category:Articles_needing_expert_attention_since_March_2009" title="Category:Articles needing expert attention since March 2009">Articles needing expert attention since March 2009</a></span> | <span dir='ltr'><a href="/wiki/Category:NPOV_disputes_from_September_2008" title="Category:NPOV disputes from September 2008">NPOV disputes from September 2008</a></span> | <span dir='ltr'><a href="/wiki/Category:All_NPOV_disputes" title="Category:All NPOV disputes">All NPOV disputes</a></span> | <span dir='ltr'><a href="/wiki/Category:Articles_to_be_expanded_since_May_2008" title="Category:Articles to be expanded since May 2008">Articles to be expanded since May 2008</a></span> | <span dir='ltr'><a href="/wiki/Category:All_articles_to_be_expanded" title="Category:All articles to be expanded">All articles to be expanded</a></span> | <span dir='ltr'><a href="/wiki/Category:All_articles_with_unsourced_statements" title="Category:All articles with unsourced statements">All articles with unsourced statements</a></span> | <span dir='ltr'><a href="/wiki/Category:Articles_with_unsourced_statements_since_May_2007" title="Category:Articles with unsourced statements since May 2007">Articles with unsourced statements since May 2007</a></span> | <span dir='ltr'><a href="/wiki/Category:Articles_with_unsourced_statements_since_May_2008" title="Category:Articles with unsourced statements since May 2008">Articles with unsourced statements since May 2008</a></span> | <span dir='ltr'><a href="/wiki/Category:Cleanup_from_May_2008" title="Category:Cleanup from May 2008">Cleanup from May 2008</a></span> | <span dir='ltr'><a href="/wiki/Category:Articles_with_sections_that_need_to_be_turned_into_prose" title="Category:Articles with sections that need to be turned into prose">Articles with sections that need to be turned into prose</a></span> | <span dir='ltr'><a href="/wiki/Category:Articles_with_unsourced_statements_since_September_2007" title="Category:Articles with unsourced statements since September 2007">Articles with unsourced statements since September 2007</a></span></div></div>			<!-- end content -->
						<div class="visualClear"></div>
		</div>
	</div>
		</div>
		<div id="column-one">
	<div id="p-cactions" class="portlet">
		<h5>Views</h5>
		<div class="pBody">
			<ul>
	
				 <li id="ca-nstab-main" class="selected"><a href="/wiki/Duloxetine" title="View the content page [c]" accesskey="c">Article</a></li>
				 <li id="ca-talk"><a href="/wiki/Talk:Duloxetine" title="Discussion about the content page [t]" accesskey="t">Discussion</a></li>
				 <li id="ca-edit"><a href="/w/index.php?title=Duloxetine&amp;action=edit" title="You can edit this page. &#10;Please use the preview button before saving. [e]" accesskey="e">Edit this page</a></li>
				 <li id="ca-history"><a href="/w/index.php?title=Duloxetine&amp;action=history" title="Past versions of this page [h]" accesskey="h">History</a></li>			</ul>
		</div>
	</div>
	<div class="portlet" id="p-personal">
		<h5>Personal tools</h5>
		<div class="pBody">
			<ul>
				<li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Duloxetine" title="You are encouraged to log in; however, it is not mandatory. [o]" accesskey="o">Log in / create account</a></li>
			</ul>
		</div>
	</div>
	<div class="portlet" id="p-logo">
		<a style="background-image: url(http://upload.wikimedia.org/wikipedia/en/b/bc/Wiki.png);" href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
	<div class='generated-sidebar portlet' id='p-navigation'>
		<h5>Navigation</h5>
		<div class='pBody'>
			<ul>
				<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li>
				<li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li>
				<li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content — the best of Wikipedia">Featured content</a></li>
				<li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li>
				<li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li>
			</ul>
		</div>
	</div>
	<div id="p-search" class="portlet">
		<h5><label for="searchInput">Search</label></h5>
		<div id="searchBody" class="pBody">
			<form action="/w/index.php" id="searchform"><div>
				<input type='hidden' name="title" value="Special:Search"/>
				<input id="searchInput" name="search" type="text" title="Search Wikipedia [f]" accesskey="f" value="" />
				<input type='submit' name="go" class="searchButton" id="searchGoButton"	value="Go" title="Go to a page with this exact name if one exists" />&nbsp;
				<input type='submit' name="fulltext" class="searchButton" id="mw-searchButton" value="Search" title="Search Wikipedia for this text" />
			</div></form>
		</div>
	</div>
	<div class='generated-sidebar portlet' id='p-interaction'>
		<h5>Interaction</h5>
		<div class='pBody'>
			<ul>
				<li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li>
				<li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li>
				<li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="The list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li>
				<li id="n-contact"><a href="/wiki/Wikipedia:Contact_us" title="How to contact Wikipedia">Contact Wikipedia</a></li>
				<li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Donate" title="Support us">Donate to Wikipedia</a></li>
				<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li>
			</ul>
		</div>
	</div>
	<div class="portlet" id="p-tb">
		<h5>Toolbox</h5>
		<div class="pBody">
			<ul>
				<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Duloxetine" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li>
				<li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Duloxetine" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li>
<li id="t-upload"><a href="/wiki/Wikipedia:Upload" title="Upload files [u]" accesskey="u">Upload file</a></li>
<li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</a></li>
				<li id="t-print"><a href="/w/index.php?title=Duloxetine&amp;printable=yes" rel="alternate" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>				<li id="t-permalink"><a href="/w/index.php?title=Duloxetine&amp;oldid=281351451" title="Permanent link to this version of the page">Permanent link</a></li><li id="t-cite"><a href="/w/index.php?title=Special:Cite&amp;page=Duloxetine&amp;id=281351451">Cite this page</a></li>			</ul>
		</div>
	</div>
	<div id="p-lang" class="portlet">
		<h5>Languages</h5>
		<div class="pBody">
			<ul>
				<li class="interwiki-de"><a href="http://de.wikipedia.org/wiki/Duloxetin">Deutsch</a></li>
				<li class="interwiki-fr"><a href="http://fr.wikipedia.org/wiki/Dulox%C3%A9tine">Français</a></li>
				<li class="interwiki-it"><a href="http://it.wikipedia.org/wiki/Duloxetina">Italiano</a></li>
				<li class="interwiki-he"><a href="http://he.wikipedia.org/wiki/%D7%93%D7%95%D7%9C%D7%95%D7%A7%D7%A1%D7%98%D7%99%D7%9F">עברית</a></li>
				<li class="interwiki-pl"><a href="http://pl.wikipedia.org/wiki/Duloksetyna">Polski</a></li>
				<li class="interwiki-pt"><a href="http://pt.wikipedia.org/wiki/Duloxetina">Português</a></li>
				<li class="interwiki-ru"><a href="http://ru.wikipedia.org/wiki/%D0%94%D1%83%D0%BB%D0%BE%D0%BA%D1%81%D0%B5%D1%82%D0%B8%D0%BD">Русский</a></li>
				<li class="interwiki-sv"><a href="http://sv.wikipedia.org/wiki/Cymbalta">Svenska</a></li>
			</ul>
		</div>
	</div>
		</div><!-- end of the left (by default at least) column -->
			<div class="visualClear"></div>
			<div id="footer">
				<div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="/skins-1.5/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>
				<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="/images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>
			<ul id="f-list">
					<li id="lastmod"> This page was last modified on 2 April 2009, at 19:48 (UTC).</li>
					<li id="copyright">All text is available under the terms of the <a class='internal' href="http://en.wikipedia.org/wiki/Wikipedia:Text_of_the_GNU_Free_Documentation_License" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="http://en.wikipedia.org/wiki/Wikipedia:Copyrights" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc.</a>, a U.S. registered <a class='internal' href="http://en.wikipedia.org/wiki/501%28c%29#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="http://en.wikipedia.org/wiki/Non-profit_organization" title="Non-profit organization">nonprofit</a> <a href="http://en.wikipedia.org/wiki/Charitable_organization" title="Charitable organization">charity</a>.<br /></li>
					<li id="privacy"><a href="http://wikimediafoundation.org/wiki/Privacy_policy" title="wikimedia:Privacy policy">Privacy policy</a></li>
					<li id="about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
					<li id="disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
			</ul>
		</div>
</div>

		<script type="text/javascript">if (window.runOnloadHook) runOnloadHook();</script>
<!-- Served by srv191 in 0.050 secs. --></body></html>
